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ABSTRACT 
Purpose: The efficacy of systemically-applied anti-cancer drugs is limited by insufficient 
selectivity, and the maximum applicable dose is limited by side effects. Improved effec-
tiveness can be achieved by targeting the cytotoxic drugs directly to the tumor. Using 
thermosensitive liposomes (TSL) as drug carriers, such targeting is achieved by control of 
temperature in the target volume. The approach can be further improved by magnetic 
resonance imaging guided local hyperthermia (HT) to visualize the content release using 
contrast agent (CA)-loaded TSL. Such visualization is considered to be an important tool 
for further improvement of HT/chemotherapy concepts based on TSL, and may facilitate 
chemodosimetry during HT. Real-time imaging of drug targeting offers better treatment 
control, and is an important step towards personalized medicine. Therefore, in this work 
quantitative assessment of HT-induced doxorubicin release (chemodosimetry) in tumors 
is examined by injecting a mixture of TSL loaded with CA or DOX into the tumors, and us-
ing MRI parameters. 
Methods: In the first part of this work a novel laser light-based HT devise was developed 
to investigate MRI-guided HT for preclinical research. To prove its effectiveness, the new 
device was compared systematically with the frequently used cold light lamp and water 
bath HT. Experiments were performed in 18 male Brown Norway rats with a syngeneic 
soft tissue sarcoma (BN 175) located on each hind leg. One tumor was heated while the 
second tumor remained unheated as a reference. Six animals were investigated per HT 
method. DPPG2-TSL were injected i.v. at a stable tumor temperature above 40 °C. Thereaf-
ter, temperature was maintained for 60 min. Total DOX concentration in plasma, tumor 
tissue, and muscle was determined post-therapy by high pressure liquid chromatography 
(HPLC). 
In the second part, the new HT device was used to identify surrogate MRI markers to 
quantify HT-enhanced DOX delivery to a heated tumor. These experiments were per-
formed in an additional six male Brown Norway rats with one syngeneic tissue soft tissue 
sarcoma (BN175) located on each hind leg. Tumor temperature was monitored using an 
intratumoral fiberoptic temperature probe. In group A (N=4), one tumor was superficially 
selectively heated by a 940 nm diode laser with a new MRI-compatible applicator, while 
the second tumor remained unheated. After reaching a temperature of 40°C, a bolus of 
mixed DPPG2-TSL and CA-TSL was administered i.v.. After 1 h, HT was stopped and the 
tumor was allowed to cool down to the temperature determined pre-HT. In group B (N=2), 
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the same experiment was performed without HT. Finally, tumors were excised for DOX 
measurement by HPLC. MRI was performed at 3T. T1-mapping using variable flip angle 
was established before and after HT. Furthermore, dynamic mapping of T1 and the phase 
were performed during the experiment. Phase change (PC), T1- and T1-related parameters 
(absolute and relative changes), or areas under the curve (AUC) of T1dyn(t) were correlat-
ed with the DOX enhancement in the corresponding tissue. 
Results: All heating methods exhibited highly effective DOX delivery by TSL with 
4.5-23.1 ng/mg found in the heated tumors. In contrast, the mean DOX concentration in 
the unheated tumors, and in abdominal muscle, was 0.5 ± 0.1 ng/mg. Independent of the 
HT methods investigated during this study, more DOX was found in the smaller tumors. By 
comparison, the water bath induced the lowest DOX delivery in large tumors, but still dis-
played a fourfold higher DOX compared to the un-heated tumors. Using the laser-based 
applicator, a DOX deposition 13 times higher than levels found in unheated tumors was 
possible for larger tumors, where levels in smaller tumors were recorded 15 times higher 
compared to the unheated tumors. Temperature gradients inside the tumor volume were 
higher with the laser and cold light lamp (– 0.3 °C/mm to – 0.5 °C /mm) than with the wa-
ter bath (– 0.1 °C/mm and – 0.2 °C/mm).  
The MRI experiments for chemodosimetry in group A showed a tumor temperature of 
41.1±1.2°C during one hour. HPLC of 18 tumor samples demonstrated highly efficient DOX 
delivery to heated tumors. Compared to unheated tumors, DOX delivery was increased by 
a factor of 9.4 ± 2.9. All investigated T1 and PC parameters were highly correlated with 
DOX concentrations measured by HPLC. Using the highly significant linear relationship of 
MRI and DOX, MRI-derived DOX parameter maps of the tumors were calculated.  
Conclusion: The comparative work with different heating methods has demonstrated that 
DPPG2-TSL drug delivery and targeting is highly effective independently from the HT 
method. Nevertheless, it was also shown that the effectiveness of the therapies is depend-
ent on the method of heating and on tumor size. Both factors must be considered in study 
designs, and when comparing results with other studies in temperature-triggered drug 
delivery. In this work, the cold light lamp and new laser applicator furnished more effi-
cient drug delivery than water bath heating.  
Furthermore, this was the first time that a mixture of TSL encapsulating either a clinically 
approved CA or DOX has been investigated for in vivo DOX concentration assessment. An 
assessment and visualization of DOX deposited in tumors was possible with the MRI. A 
variety of static or dynamic MRI surrogate markers based on T1 or phase appeared to cor-
relate with the DOX concentration in the tumor tissue. MR thermometry was affected by 
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CA-TSL, but phase information was confirmed to be suitable for DOX assessment. Local 
DOX differences in the tumors indicated the need for visualization of drug release for fur-
ther improvement of targeted chemotherapy.  
In conclusion, promising MRI surrogate parameters were also identified for the assess-
ment of DOX tissue concentration when using a mixture of CA-TSL and DOX-TSL.  
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ZUSAMMENFASSUNG 
Motivation: Die therapeutische Wirkung von systemisch verabreichten Chemotherapeu-
tika in soliden Tumoren ist limitiert durch die fehlende Selektivität der Medikamente und 
die maximal mögliche verabreichbare Dosis welche durch Nebenwirkungen begrenzt ist. 
Die Effektivität kann durch ein gezieltes Freisetzen der Medikamente im Tumor gesteigert 
werden. Mit Hilfe von temperatursensitiven Liposomen (TSL) ist es möglich die Freiset-
zung des Medikaments durch lokaler Temperaturerhöhung (HT) zu steuern. Eine Mög-
lichkeit zur weiteren Verbesserung dieser Methodik bietet die Visualisierung der Wirk-
stofffreisetzung mit Hilfe der Magnetresonanztomographie (MRT) gestützten lokalen HT. 
Dies wird durch die Beladung der TSL mit MRT Kontrastmittel (CA) erreicht. Die Visuali-
sierung wird als Voraussetzung zur Verbesserung der HT kombiniert mit der Chemothe-
rapie mit TSL gesehen und ermöglicht eine Chemodosimetrie während der HT. Die Analy-
se der Wirkstoffaufnahme in den Tumor in Echtzeit ermöglicht eine bessere Therapiesteu-
erung und ist ein Schritt hin zur personalisierten Medizin. Ziel dieser Arbeit war daher die 
quantitative Bestimmung des durch HT im Gewebe freigesetzten Medikaments im Tumor 
unter Verwendung verschiedener MRT Parameter und mit Hilfe von DOX beladenen TSL 
gemischt mit CA beladenen TSL. 
Methoden: Um eine vorklinische Untersuchung zur MRT-überwachten Hyperthermie zu 
ermöglichen wurde ein MR-kompatibler, auf Laserlicht basierender HT-Applikator entwi-
ckelt. Die Effektivität dieses neuen Applikators wurde in einer ersten Studie systematisch 
durch den Vergleich mit etablierten experimentellen Erwärmungsmethoden wie einer 
Kaltlichtlampe und einem Wasserbad getestet. Bei 18 männlichen „Brown Norway“ Ratten 
mit syngenen Weichteilsarkomen (BN 175) an beiden Hinterläufen wurde jeweils nur ein 
Tumor erwärmt. Der zweite, nicht erwärmte Tumor diente als Referenz. Die Wirkung der 
drei Erwärmungsmethoden auf die erreichte DOX-Konzentration wurde an jeweils 
6 Tieren untersucht. Nach Erreichen einer stabilen Tumortemperatur von über 40°C unter 
Verwendung einer der drei HT-Methoden wurde eine Mischung aus DPPG2-TSL mit ver-
kapseltem DOX oder CA intravenös injiziert. Anschließend wurde die Tumortemperatur 
über weitere 60min stabil gehalten. Nach der Behandlung wurde die DOX Konzentration 
im Plasma, im Tumor und im Muskelgewebe mit der Hochdruckflüssigkeitschromatogra-
phie (HPLC) gemessen. 
Mit dem neuen Laserlicht basierten HT-Applikator wurden in einer zweiten Studie mögli-
che MR Parameter für eine MR-gestützte Chemodosimetrie an 6 männlichen „Brown Nor-
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way“ Raten mit jeweils einem syngenen Weichteilsarkom (BN 175) an jedem Hinterlauf 
untersucht. In einer Gruppe (A) mit 4 Tieren wurde jeweils ein Tumor mit dem neuen 
MRT kompatiblen Laserapplikator erwärmt, während der zweite nicht erwärmte Tumor 
als Kontrolle diente. Nachdem im erwärmten Tumor eine stabile Temperatur über 40 °C 
erreicht wurde, ist ein Gemisch aus DPPG2-TSL und CA-TSL i.v. injiziert worden. Nach ei-
ner Stunde wurde die Erwärmung gestoppt und der Tumor kühlte bis auf die Temperatur 
vor der Erwärmung ab. In der zweiten Gruppe (B, N=2) wurde das gleiche Experiment, 
jedoch ohne Erwärmung durchgeführt. Die Tumortemperatur wurde bei allen Untersu-
chungen mit einer intratumoral gelegten fiberoptischen Temperatursonde überwacht. 
Nach Abschluss wurden die Tumore zur Analyse mit der HPLC entnommen. Die MRT-
Bildgebung bei 3T fand kontinuierlich während des ganzen Verlaufs statt. Mit der variab-
len Flipwinkel Methode wurden vor und nach Hyperthermie T1-Parameterkarten erstellt. 
Zusätzlich sind zeitaufgelöste T1 Messungen und Phasenmessungen während der Experi-
mente durchgeführt worden. Die Phasenänderungen, die T1-Relaxationszeiten und weitere 
T1 abhängige Parameter (absolute und relative Änderung oder die Fläche unter der Kurve 
(AUC) der T1-Zeitverlaufs) wurden mit der DOX Anreicherung im dazu gehörigen Gewebe-
volumen verglichen.  
Ergebnisse: Alle verwendeten Erwärmungsmethoden führten zu einer deutlich verbes-
serten Anreicherung von DOX (4,5-23,1 ng/mg) durch den Einsatz von TSL im erwärmten 
Tumor. Im Gegensatz dazu lag die durchschnittliche DOX Konzentration im nicht erwärm-
ten Tumor und im abdominellen Muskelgewebe bei 0,5 +- 0,1 ng/mg. Unabhängig von der 
verwendeten HT Methode wurde mehr DOX in den kleineren Tumoren gefunden.   
Das Wasserbad führte zur geringsten Anreicherung in den großen Tumoren, zeigte jedoch 
im Gegensatz zu den nicht erwärmten Tumoren immer noch eine vierfach höhere DOX-
Anreicherung. Die Erwärmung mit dem Laserapplikator führte zu einer 13-fach höheren 
DOX Anreicherung für die großen Tumore und einer 15-fach höheren DOX-Anreicherung 
in den kleinen Tumoren im Vergleich zum nicht erwärmten Tumor. Die Temperaturgradi-
enten im Tumor bei Erwärmung mit dem Laserapplikator oder der Kaltlichtlampe  
( - 0,3 °C/mm bis - 0,5 °C/mm) waren höher im Vergleich zu denen des Wasserbads  
( - 0,1 °C/mm bis -0,2 °C/mm) 
Die MRT-Experimente im zweiten Teil der Arbeit zur Chemodosimetrie wurden bei einer 
mittleren Tumortemperatur von 41.1 ± 1,2 °C während einer Stunde in Gruppe A durchge-
führt. Die HPLC Analyse der 18 Tumorproben zeigte eine sehr effiziente DOX Anreiche-
rung im erwärmten Tumor im Vergleich zu den nicht erwärmten Tumoren. Die DOX An-
reicherung war um einen Faktor von 9,4 ± 2,9 höher. Alle untersuchten T1 und Phasenpa-
rameter besaßen eine hohe Korrelation mit der HPLC gemessenen DOX Konzentration. 
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Unter der Verwendung der hoch signifikanten linearen Abhängigkeit der MR Parameter 
und der DOX-Werte wurden DOX Konzentrationskarten der Tumore berechnet. 
Fazit: Die Vergleichsstudie mit unterschiedlichen Erwärmungsmethoden hat gezeigt, dass 
unabhängig von der Erwärmungsmethode ein sehr effektiver zielgerichteter Medikamen-
tentransport und –freisetzung mit DPPG2-TSL erreicht wird. Gleichwohl ist die Höhe der 
Effektivität sowohl von der Methode als auch von der Tumorgröße abhängig. Diese beiden 
Faktoren sollten somit in weiteren Studien und bei dem Vergleich von Ergebnissen ver-
schiedener Studien zur temperaturinduzieren Medikamentenfreisetzung berücksichtigt 
werden. In dieser Studie ist eine effektivere Medikamentenanreicherung im Tumorgewebe 
durch die Erwärmung mit der Kaltlichtlampe oder dem neu entwickeltem Laserlichtappli-
kator im Vergleich zur Erwärmung mit dem Wasserbad erreicht worden. 
Erstmals konnte auch gezeigt werden, dass auch eine Mischung aus TSL, die entweder ein 
klinisches zugelassenes MR CA oder DOX enthielten, zur Messung einer in vivo 
DOX-Gewebekonzentration verwendet werden kann. Eine Vielzahl von statischen und 
dynamischen T1 oder phasenbasierenden MRT Parametern korrelierten mit der DOX Kon-
zentration im Tumorgewebe. Damit waren eine Abschätzung des im Tumorgewebe plat-
zierten DOX mit dem MRT und eine entsprechende Visualisierung der DOX-Verteilung im 
Tumor möglich. Die MR-Thermometrie wurde durch die CA-TSL beeinträchtigt, jedoch 
konnten die gleichen Phaseninformationen stattdessen für die DOX-Abschätzung genutzt 
werden. Lokale Unterschiede in der DOX-Gewebekonzentration zeigen, dass die Visualisie-
rung der Medikamentenfreisetzung und der Medikamentenaufnahmen für eine weitere 
Verbesserung der zielgerichteten Chemotherapie wichtige zusätzliche Informationen lie-
fern können. 
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1. INTRODUCTION 
In highly developed regions worldwide, cancer has been the second most common cause 
of death over the past few decades, with circulatory diseases being the most responsible 
for fatalities [1]. Different methods of tumor therapy are available to patient, such as sur-
gery, radiation therapy and chemotherapy, and hyperthermia. These methods are used 
depending on the type, grade and stage of the tumor, and are generally used in combina-
tion. Due to the severe side effects of chemotherapy, different improvements to the thera-
py have been developed. Regional Hyperthermia (HT)—in combination with chemothera-
py [2,3] or radiation [4–6]—has been shown to be an effective therapeutic modality for 
cancer treatment. A significant improvement in tumor control and overall survival was 
observed with the combined therapy in comparison to the stand-alone therapy for high 
risk soft tissue sarcomas [2,7]. Radio frequency (RF) is commonly used to induce mild HT 
in tumors [8], and high intensity focused ultrasound (HIFU) is currently under develop-
ment as well [9]. 
To reduce side effects and to improve the therapy provided by chemotherapy, mild HT 
combined with thermosensitive liposomes (TSL) as nano-carrier systems has been the 
subject research for decades. Studies have demonstrated that HT can be used to trigger 
drug release from nano-carriers containing chemotherapeutics such as doxorubicin and 
higher drug concentrations in tumors can be achieved. As RF and HIFU are proven meth-
ods used to heat controlled volumes, it is possible to combine these technologies with the 
TSL nano-carriers to achieve a triggered local release of chemotherapeutic drugs into the 
tumor tissue upon externally-controlled heating [10]. Lysolipid-based TSL with encapsu-
lated doxorubicin (DOX) have been developed and have recently entered human clinical 
trials [11].  
The mechanism of TSL nanocarrier action is their HT-induced ultra-fast intravascular DOX 
release inside of the heated tumor vasculature, which significantly increases the concen-
tration of bioavailable drug in the interstitial space compared to conventional PEGylated 
liposomes or free drugs [12]. Alternative targeting concepts for TSL include a pre-HT 
treatment to increase their extravasation by the enhanced permeability retention (EPR) 
effect [13,14], combined with a second heat trigger to increase interstitial drug release 
[15]. In recent years, an improved TSL formulation for intravascular drug release based on 
the synthetic phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2) has 
been developed [16–20] and is currently under preclinical investigation in a feline phase I 
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study. Hence, the control of temperature in the target volume is vital to optimal targeting 
and triggering, parallel to the development of new nano-carriers, and there is a need for 
better therapy control for HT in combination with drug-loaded TSL.  
Temperature monitoring and control over the entire volume is necessary in order to avoid 
HT-induced necrosis and cell death and thus achieve an optimal therapeutic outcome in 
order to sufficiently heat up the whole volume of interest in a controlled manner. Different 
methods such as temperature probes can be used for these purposes, but probe based 
methods only provide one- or two-dimensional locally confined temperature information. 
In contrast, magnetic resonance imaging (MRI) provides different noninvasive methods 
for temperature mapping during mild HT, and was thus developed by several study groups 
[21–26].  
For effective radiation therapy, precise and uniform dose coverage of the target volume is 
crucial [27]. An analogous drug dose painting is therefore an advancement towards per-
sonalized chemotherapy and more accurate predictions about the likely treatment re-
sponse. In addition to invasive methods of drug quantification such as biopsy, histology, or 
micro dialysis, some non-invasive methods for drug dose painting—SPECT, CT, PET, and 
MRI—are examined in several studies [28–31]. All of these methods present their own 
advantages and disadvantages in areas such as the spatial and temporal resolution, quanti-
tative measurement, and covered volume. CT scans, for example, demand ionizing radia-
tion, but provide a high spatial and temporal resolution. SPECT and PET provide quantita-
tive data for radio-labelled pharmaceuticals, but require radioisotopes with generally 
short half-lives and yields only limited spatial resolution. MRI, however, combines high 
spatial and temporal resolution with no requirement for ionizing radiation and a good 
sensitivity for common CAs. 
In the first part, this work investigates the effectiveness of mild HT-induced drug release 
from TSL in small animals with subcutaneous implanted syngeneic tumors by juxtaposing 
widely applied methods such as water baths or a cold light lamp with a newly developed 
MR-compatible laser light-based device (Chapter 3).  
In the second part,, different static and dynamic MR parameters are examined using the 
new device, and their potential to serve as a surrogate marker for drug dose painting dur-
ing mild HT-induced drug release from TSL is evaluated (Chapter 4). As temperature is the 
trigger for drug release from TSL, 3D information of temperature distribution or local drug 
concentration is suggested as the next area of improvement in further research in order to 
provide a more effective therapy. 
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2. BASICS 
2.1 CHEMOTHERAPY WITH DOXORUBICIN 
Chemotherapy is a method of treating cancer with cytotoxic drugs, which can be naturally 
or synthetically produced. There are more than 50 drugs used, alone or in combination, to 
treat more than 100 types of cancer [32]. Systemic chemotherapy is accompanied by sys-
temic side effects that limit the usable dosage. For experiments with cytotoxic drugs in this 
work, the drug Doxorubicin (DOX) was used. 
Doxorubicin is an anthracycline antibiotic used for systemic treatment. It works by inter-
calating DNA and RNA, thereby causing an inhibition of type II toboisomerase, disturbance 
in DNA synthesis, and an increase in radicals. This affects DNA and membrane damage, 
crosslinks, and oxidative stress, among other effects [33]. DOX is used in the treatment of 
cancers such as mamma carcinoma, soft tissue sarcoma, and osteosarcoma. Common side 
effects of the treatment include hair loss, nausea, vomiting, myelosuppression, and cardio 
toxicity [34]. Therefore, the therapy would be improved by a targeted release of DOX to 
reduce side effects. 
DOX is also useful for the development of new therapy strategies due to its fluorescence 
and rapid intercalation with DNA. These properties can assist with analysis of tissue con-
centration. 
2.2 HYPERTHERMIA 
To understand the benefits of mild hyperthermia and distinguish it among other heat 
therapies, this section begins with a short introduction. Hyperthermia (HT) in cancer ther-
apy is defined as a treatment in which body tissue is exposed to temperatures between 39 
to 42 °C for a period of time (usually 60 min). This approach causes less significant chang-
es in the treated tissue compared to major tissue change induced by coagulation or abla-
tion. Regional or local HT must also be distinguished from whole-body HT, which involves 
body temperatures around 39°C and is not restricted to a single organ or part of the body. 
Likewise, thermoablation is distinguished as a treatment where temperatures above 60 °C 
are administered to a small tissue volume.  
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Heating of a target area can be accomplished using a number of techniques. In a clinical 
setup, regional deep HT with radio frequency field is common. Radio frequency transmit-
ters located in specific areas around the body are used to heat up the tissue in the target 
area. 
At a normal body temperature of 37 °C, permeability in the blood vessels of tumorous tis-
sue manifests itself differently than permeability in healthy tissue. Heating of the tumor 
causes an increase of perfusion and permeability of blood vessels, even in normally im-
permeable tumor vessels [11]. For tumor therapy—in particular for use in drug enhance-
ment within tumor tissue—perfusion and the permeability of blood vessels are crucial. 
These factors can be meaningfully influenced by HT [8,35]. In induced mild HT, direct tu-
mor cell death is not the therapeutic goal as the tissue temperatures do not rise high 
enough to achieve coagulation necrosis. The main objective of mild HT, aside from the 
potential immune effects, is its synergistic effect with chemotherapy or radiation therapy 
[36]. For this, a constant temperature in the range of 39 °C to 42 °C for a minimum of one 
hour is necessary. This induces positive effects such as inhibition of DNA-repair caused 
through chemotherapy or radiotherapy, changes in perfusion and oxygenation of tumor 
tissue, change in the extracellular pH, liberation of heat shock proteins and stimulation of 
the immune system [37]. Due to these effects, HT is approved as a standard treatment mo-
dality in combination with chemotherapy within a multimodal treatment strategy for high 
risk soft tissue sarcoma [38]. It must be noted that mild HT has to be used in combination 
with radiotherapy or chemotherapy to prompt a significantly better therapy outcome over 
chemotherapy or radiotherapy alone [2]. 
2.3 LIPOSOMES 
Due to the cytotoxic drugs’ lack of tumor specificity and severe short-term side effects of 
chemotherapy, new strategies such as the use of liposomes as drug carrier are urgently 
needed for a better therapy outcome. Liposomes as nanocarrier are capable of incorporat-
ing drugs inside their aqueous interior, or to integrating drugs into their membranes. They 
were described first by Bangham et al. 1965 [39] and have been improved for tumor 
treatment since the late 70s . The lipids used in this work were developed by Eibl et al. 
[40]. The next section briefly introduces the release kinetics and effect of liposomes.  
Liposomes are synthetically-produced vesicles consisting of a phospholipid bilayer mem-
brane surrounding an aqueous interior. These membranes are biocompatible and the 
phospholipids can be enzymatically metabolized mainly in the liver [41]. The phospholip-
ids themselves are composed of hydrophobic tails and hydrophilic head groups (Figure 1). 
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Figure 1: Chemical structure of the used phospholipids DPPC, DSPC, and DPPG2 and illustra-
tion of the lamellar structure after mixing in aqueous solution. 
In the clinic, the main representative of a liposomal chemotherapy using doxorubicin is 
Caelyx/Doxil (Janssen Pharmaceutica NV, Bersee, Belgium, or LP, Horsham, USA). Cae-
lyx/Doxil belongs to the group of non-TSL with long circulating times and thereby takes 
advantage of the enhanced permeability and retention (EPR) effect. Despite potential pas-
sive accumulation in tumor tissue, these drugs have not exhibited improved antitumor 
efficacy due to a generally weak EPR-effect in solid human tumors and a strong liposomal 
membrane disabling DOX leakage. However, there is a reduction of cardiotoxicity with 
these liposomes [42]. Thermodox (Celsion Corporation, Lawrenceville, USA) instead is a 
thermosensitive liposome (TSL), which facilitates release of the encapsulated drug at tem-
peratures higher than 39°C. Such a mechanism promotes a higher drug concentration in 
heated tissue, and thus fewer side effects and a better therapy outcome. There are ongoing 
clinical studies regarding this method, which is based on lysolipids [11]. The disadvantage 
of TSL based on lysolipids is their shorter circulation time at normal body temperature. As 
a result, fewer liposomes reach the target tissue, reducing the effectiveness of the therapy. 
Thermosensitive functionality of liposomes is driven by the phase transition of the lipids, 
which was first described by Yatvin et al. in 1978 [43]. The phase transition can be in-
duced by heating the lipids above their specific phase transition temperature, Tm. beneath 
Tm, the liposome membrane is in a solid-gel phase, thus the densely-packed lipids prevent 
a diffusion of water or drugs through the membrane. Above the phase transition tempera-
ture, lipids enter into a liquid-crystalline phase, which alters the structure of the mem-
brane until diffusion of macromolecules can occur. 
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This phase transition is specific for each phospholipid type (Table 1), thus the phase tran-
sition temperature of the liposomes can be defined by mixing different lipids.  
The liposomes employed in this work are TSLs based on the novel synthetic phosphatidyl-
diglycerol (DPPG2) that lacks lysolipids. Elimination of lysolipids results in a longer circu-
lation time at body temperature and a rapid drug release at Tm (chapter 3.2.1), which are 
mandatory for effective drug delivery by TSL.  
Lipid hydrophobic tail hydrophile head group Tm [°C] 
DPPC palmitic acid phosphocholine 41.5 
DSPC stearic acid phosphocholine 56.0 
DPPG2 palmitic acid phosphodiglycerin 39.7 
Table 1: Different phospholipids with their phase transition temperatures Tm  
2.4 BIOMEDICAL OPTICS 
The effect of light on biological tissue has been leveraged in medical therapy and diagnos-
tics for a long time. From an optical point of view, tissue is a complex medium due to its 
inhomogeneous microscopic and macroscopic scale [44]. Therefore, the effects on tissue 
are dependent on the wavelength, light power, irradiation time, and tissue attributes such 
as reflection, scattering, absorption, polarization, and fluorescence. This section provides a 
short introduction to biomedical optics and its application in medicine in order to inform 
later discussion about a suitable laser system for mild HT with a high penetration depth in 
biological tissue. A high penetration depth is necessary to obtain an as homogenous heat-
ing pattern as possible. For further information, the author also refers to Jelinkova et al. 
2013 [45]. 
2.4.1 INTERACTION OF LASER RADIATION WITH TISSUE 
Penetration depth of light into tissue depends mainly on three factors: reflection, scatter-
ing and absorption [45].  
Reflection 
Reflection determines the amount of radiation that penetrates into the tissue. This effect 
plays an important role for transparent tissue; however for opaque tissue, reflection has 
only a minor influence and scattering and absorption are more dominant [45]. 
Scattering 
Scattering occurs when the radiation is forced to deviate from its straight trajectory. Scat-
tering emits the light in all directions around the scattering center and is not limited by a 
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given direction. Release of energy in the tissue is dependent on factors such as the wave-
length, light polarization, and the size of the molecule [45]. 
Absorption 
For therapeutic treatment, the medium’s ability to absorb electromagnetic radiation is 
important. Absorption of electromagnetic radiation depends on factors such as: the elec-
tronic structure of the atoms and molecules, radiation wavelength, and the thickness of the 
medium. In biological tissue, absorption is mainly caused by water molecules, although 
macromolecules, e.g. proteins and pigments, also play a role [45].  
2.4.2 LASER LIGHT FOR MEDICAL APPLICATIONS 
Lasers are mostly used for three forms of treatment in medicine: laser surgery, thermal 
therapy, and photodynamic therapy. The application of a laser is defined by its wavelength 
and pulse modulation.  
Absorption of optical radiation in water is highest in the ultra violet (UV) 
(100 nm - 380 nm) and long wave infrared ranges (IR). Biological tissue usually contains a 
great deal of water, thus the short wave and long wave radiation is absorbed easily. For 
visible light and near IR, hemoglobin and melanin determine absorption, as demonstrated 
in Figure 2 [46].  
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Figure 2: Absorption of optical radiation depending on wavelength for different constituents 
of tissue. Typical wavelength for different laser types are marked with arrows and corre-
sponding laser medium. (from [45] with permission by Elsevier GmbH) 
The nature and severity of the tissue reaction depend mainly on the irradiation time and 
intensity (Figure 3). Therefore, photochemical reactions would be triggered by a long ir-
radiation time (several minutes or hours) in the range of less than one Watt per square 
centimeter (cm²). For radiation in the visible- or infrared-light range, molecules can ab-
sorb radiation and release their energy in the surrounding tissue. This can lead to an in-
creased presence of free radicals (this effect can be enhanced by a photosensitizer i.e. for 
photodynamic therapy (PDT)), which harm genetic material (DNA) and oxygen proteins. 
Light radiation in the UV range can also cause direct damage to DNA.  
For short irradiation times (few seconds to milliseconds) and a power of a few Watts per 
cm² up to one Megawatt, different thermal effects are observed. These effects range from a 
slight warming of the tissue or denaturation of protein, to charring and black staining of 
the tissue. Such thermal effects are harnessed therapeutically for laser surgery or laser-
induced thermotherapy (LITT). With short irradiation times of nano- to microseconds and 
an irradiation power of megawatts per cm², the target tissue vaporizes, while the sur-
rounding tissue is barely warmed.  
Even higher power—in the order of Gigawatts per cm² in tissue—creates plasma. This 
creates a shock wave that spreads out and destroys tissue mechanically. This is the basis 
for disruption of kidney- or gallstones (lithotripsy). 
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Figure 3: Dependency of light effects on tissue in relation to radiation time and power of 
applied light (adapted from Berlien [47,48]) 
In biological tissue, absorption is weak in the near-infrared (NIR) range, which is defined 
as 600 nm – 1350 nm wavelengths [49]. For the NIR window, a free path of about 0.1mm 
can be assumed between photon-scattering events. This free path results in an absorption 
length from 10 mm – 100 mm [50]. For subcutaneous mild HT, a wavelength in the NIR 
window is necessary. 
2.5 MR-IMAGING 
Nuclear Magnetic Resonance (NMR) was discovered by Bloch and Purcell in 1946 and is 
based on different energy levels in an atom nucleus [51,52]. MRI uses this effect to resolve 
the distribution and relaxation properties of hydrogen atoms. This chapter only provides 
an overview of MRI, principles of tissue quantification, and temperature mapping—all of 
which were used for the following experiments. For further information, the reader is re-
ferred to books by Haacke and Bernstein [53,54]. 
2.5.1 NUCLEAR SPIN AND NET MAGNETIZATION 
The properties of an atomic nucleus are described, among other things, by the number of 
protons Z and the mass number N, as well as its nuclear spin quantum number I, which can 
be either zero, a half-integer, or an integer. For the hydrogen nucleus 1H, which is used 
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mostly in clinical MRI, the spin quantum number is I = ½. For all nucleuses with a spin 
quantum number nonequal to zero, the magnetic moment μ can be written with: 
𝜇 = 𝛾𝐼 
1 
where γ is the gyromagnetic ratio, which is characteristic for a specific nucleus. The hy-
drogen nucleus has a gyromagnetic ratio γ at 2.675*108 rad T-1 s-1. 
Within a large external magnetic field (B0), nuclear spins “align” with the external magnet-
ic field. This behavior can be described by 
𝑑𝜇
𝑑𝑡
= 𝛾𝜇 × ?⃑⃑? 
2 
This equation implies that a given magnetic moment (spin) will precess around the axis of 
the B0 field, with the field strength B and with the Larmor frequency 𝜔0 = 𝛾𝐵. The sum of 
all magnetic moments generated from the nuclei in a sample is called the net magnetiza-
tion (Mz). In absence of an external field, the net magnetization vanishes because the direc-
tion of these magnetic moments is randomly distributed in a sample. Within an external 
magnetic field, nuclear spins align either parallel (P↑) or antiparallel (P↓) to the external 
field, resulting in a net magnetization in the direction of B0 that can be described with [55]: 
𝑀𝑧 =
ħ𝛾
2
(𝑃↑ − 𝑃↓) ≈
ħ2𝛾2𝐵0
4𝑘𝑇
 
3 
were ħ denotes the reduced Planck constant and k for the Boltzmann constant. This ap-
proximation is valid when 𝑘𝑇 > 𝛾ħ𝐵0. For a typical MRI setting i.e. a magnetic field of 1.5T 
and room temperature, the polarization of the spins is 10-6 [55]. This shows that strong 
magnetic fields are required to yield a measurable magnetization in a sample. Given that 
the hydrogen nucleus has the highest γ of all stable nuclei (𝛾 = 2.675 ∗ 108  
rad
Ts
), and the 
percentage of water is high (~ 70 %) in the human body, the hydrogen nucleus is mainly 
used for clinical MR-imaging. 
2.5.2 RADIOFREQUENCY EXCITATION 
With a radiofrequency (RF) pulse B1(t) the net magnetization Mz can be tipped out of their 
state of equilibrium. Assuming that B1(t) rotates around the magnetic field 𝐵0⃑⃑ ⃑⃑ = 𝐵0 ∗ ?̂? 
with a frequency ⍵p the RF pulse can be written as [53]: 
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𝐵1(𝑡) = 𝐵1(𝑥 cos(𝜔𝑝) + ?̂? sin(𝜔𝑝)) 
4 
Now the resulting magnetization in a constant magnetic field B0 can be described with 
𝑑𝑀(𝑡)
𝑑𝑡
= 𝛾 ∗ 𝑀(𝑡) × (𝐵0 + 𝐵1(𝑡)) 
= 𝛾 ∗ 𝑀(𝑡) × (𝐵1 cos(𝜔𝑝𝑡)𝑥 + 𝐵1 sin(𝜔𝑝𝑡) ?̂? + 𝐵0?̂?) 
5 
To simplify the equation, this system is transformed from a stationary coordinate system 
into a rotating coordinate system with x’ = x cos(⍵p t) + y sin(⍵p t); 
y’ = -x sin(⍵p t) + y cos(⍵p t); and z’ = z, which results in 
𝑑𝑀(𝑡)
𝑑𝑡
= 𝛾 ∗ 𝑀(𝑡) × (𝐵1𝑥′̂ + (𝐵0 −
𝜔𝑝
𝛾
) 𝑧′̂) 
6 
Thus, the magnetization rotates in the rotating system around the axis of the effective 
magnetic field Beff. If ⍵p is equal to the Larmor frequency, only the x’-component of Beff 
remains and the magnetization can be written as 
𝑑𝑀(𝑡)
𝑑𝑡
=  𝛾 ∗ 𝑀(𝑡) × 𝐵1𝑥′̂ 
7 
If a field on-resonance B1 is applied for a finite time tp, the net magnetization can be tipped 
by an angle α with 
𝛼 = 𝛾𝐵1𝑡𝑝 
8 
After switching of the RF pulse, the resulting magnetization M⏊ induces a signal in a re-
ceiver coil, which is the signal detected in NMR-measurements. 
2.5.3 RELAXATION 
Interactions between spins lead to a statistically-changing local magnetic field that chang-
es the magnetization relaxation of the spin. This relaxation is characterized by the longitu-
dinal relaxation time T1 and the transversal relaxation time T2. [53] 
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The longitudinal or spin-lattice relaxation time T1 characterizes the restoration of the lon-
gitudinal component of the magnetization Mz. This relaxation is induced by a spin-lattice 
interaction and the surrounding tissue absorbs the released energy. 
The transversal or spin-spin relaxation time T2 is characterized by the decay of the trans-
verse magnetization. Here, the coherent transverse magnetization that exists after a RF 
pulse is destroyed by an interaction between the spins. This destruction leads to a loss of 
phase coherence between the different spins. Furthermore, every spin is exposed to a fluc-
tuating field, which varies the magnetic fields in Mz direction and hence the precession 
rate and thus the phase of the spins. This relaxation process is an entropic effect, and there 
is no energy exchange with the environment. 
Due to magnetic field inhomogeneity, there is a faster decay of the MR-Signal due to the 
spin-spin relaxation. Static variations in B0 lead to an additional phase, which is called the 
T2* relaxation. In contrast to the T2-relaxation, the T2*-relaxation can be reversed by in-
verting the phase. The resulting decay of the transverse magnetization is described by the 
T2* relaxation time and can be written as: 
1
𝑇2
∗ =
1
𝑇2
+
1
𝑇2
′ 
9 
Longitudinal (T1) and transversal relaxation times (T2, T2*) depend on e.g. different tissue 
types and the magnetic field strength B0. Typical T1 and T2 relaxation times for tissue are 
shown in Table 2. 
Tissue 
T1 relaxation time T2 relaxation time 
1.5 T 3 T 1.5 T 3 T 
muscle 1130 ± 91.7 1420 ± 38.1 35.3 ± 3.85 31.7 ± 1.9 
cartilage 1060 ± 155 1240 ± 107 42.1 ± 7.05 36.9 ± 3.81 
synovial fluid 2850 ± 279 3620 ± 320 1210 ± 140 767 ± 48.8 
subcutaneous fat 288 ± 8.42 371 ± 7.94 165 ± 5.5 133 ± 4.43 
Table 2: T1 and T2 relaxation times for 1.5 T and 3.0 T with SD in different tissue [56] 
These relaxation effects are descripted by Bloch 1946 with equation 10 [51].  
𝑑𝑀𝑥
𝑑𝑡
= 𝛾(?⃑⃑⃑? × ?⃑⃑?)
𝑥
−
𝑀𝑥
𝑇2
 
𝑑𝑀𝑦
𝑑𝑡
= 𝛾(𝑀 × 𝐵)𝑦 −
𝑀𝑦
𝑇2
 
𝑑𝑀𝑧
𝑑𝑡
= 𝛾(𝑀 × 𝐵)𝑧 −
𝑀0 − 𝑀𝑧
𝑇1
 
10 
Basics 19 
 
With the introduction of the complex transversal magnetization 𝑀⏊ = 𝑀𝑥 + 𝑖𝑀𝑦 and a 
constant magnetic field B = (0,0,B0)⏊ this equation can be simplified to 
𝑀⏊(𝑡) = 𝑀⏊(0)𝑒
−𝑖𝜔0𝑡𝑒
−
𝑡
𝑇2 
𝑀𝑧(𝑡) = 𝑀0 − (𝑀0 − 𝑀𝑧(0))𝑒
−
𝑡
𝑇1 
11 
This is called the free induction decay (FID). After an RF pulse, the transversal magnetiza-
tion precesses around the B0 axis with the Larmor frequency, and decays with 𝑒
−
𝑡
𝑇2 
whereas the longitudinal magnetization recovers with 1 − 𝑒
−
𝑡
𝑇1. 
2.5.4 SPATIAL ENCODING AND K-SPACE 
For MR-imaging, this NMR-signal needs to be modified to provide a spatial encoding. Here 
a short introduction is given about the spatial encoding and the resulting k-space. 
Spatial encoding 
In a homogeneous magnetic field, all spins have the same Larmor frequency ⍵0, and the 
NMR-signal after an RF pulse contains no information about the position of the spins. 
Therefore, spatial encoding is essential for MR-Imaging, which relies on applying magnetic 
field gradients. The first step in approaching the problem is to reduce the dimension of the 
volume of excitation by applying a slice selection. A two-dimensional slice in one direction 
is selected and yields to a two-dimensional matrix that must be resolved. Slice encoding in 
the x-y plane is achieved by applying a linear magnetic gradient Gz in the z-direction, 
which leads to a location-dependent Larmor frequency in the z-direction, and a simultane-
ous excitation RF pulse with the frequency ⍵a and bandwidth ⍵(z).  
𝜔𝑧 = 𝛾(𝐵0 + 𝐺𝑧) 
12 
The properties of the gradient and the RF pulse bandwidth ⍵(z) determine the position and 
the thickness of the excited slice, which is illustrated in Figure 4. 
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Figure 4: Principle of slice selection. For a defined Gradient Gz and an RF pulse with a band-
width ⍵(z), a slice with thickness Δz is excited. 
For in-plane encoding, two further gradients are necessary: the frequency and the phase-
encoding gradient. A signal with a high bandwidth is generated by adding a linear gradient 
G(x) during the readout. With a Fourier transformation, every frequency can be assigned to 
a specific place in the direction of the gradient. Determining the remaining dimensions 
requires that a phase-encoding gradient G(y) be added after the RF pulse, and before 
readout. To satisfy the criterion of Nyquist, this cycle is repeated with an incrementally 
altered gradient for phase-encoding until enough data is received to calculate the image 
with the target spatial resolution in phase direction.  
k-space 
The acquired signals create the so-called “k-space”. With these data, the image can be re-
constructed by Fast-Fourier transformation. Each point in the k-space corresponds with 
one spatial frequency in the whole image. Low spatial frequencies are found in the center 
of k-space and high spatial frequencies correspond to peripheral points in k-space.  
The acquisition of the k-space is controlled by the strength of the gradients. Thus with 
varying gradients different sampling grids can be acquired (Figure 5). The position 
(kx ky kz) of data points in this grid defines the strength of the gradients. Here an acquisi-
tion with Cartesian coordinate system will be used. A schematic diagram for k-space filling 
is shown in Figure 5. 
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Figure 5: The Signal modified with gradients is sampled with a given frequency and resulting 
magnitude is transferred into the k-space. Position in ky-direction is set by the phase-
encoding gradient, position in kx is modified by frequency encoding gradient during signal 
readout.  
2.5.5 SEQUENCES 
Every sequence in MR-imaging consists of essential components such as an RF excitation 
pulse, gradients for spatial encoding, and signal readout combined with an echo type (spin 
echo, gradient echo, …). There are different sequence types with different advantages and 
limitations.  
SpinEcho sequence 
The spin echo (SE) sequence is the most basic sequence and was developed by Carr and 
Purcell 1954 [57]. The principle of the spin echo sequence is described in Figure 6 . A 90° 
RF pulse with a 180° pulse is combined. With this technique, the T2* effect can be reversed 
using the 180-degree refocusing pulse. It flips the magnetization by a 180° pulse at TE/2 
after excitation were TE is the echo time, which induces a revocation of phase difference 
between spins. This leads to an echo after TE. After a defined repetition time TR, this se-
quence cycle is repeated until k-space is completely acquired. 
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Figure 6: Schematic of a spin echo sequence with RF pulse, gradients, and generated spin 
echo. This schema is repeated after TR. 
Gradient Echo sequence 
Gradient echo (GRE) is a class of pulse sequences that was developed primarily for rapid 
scanning; it is widely used in dynamic 3D volume imaging [58]. In contrast to the spin echo 
sequence, the echo is generated with a negative gradient, which is applied after the initial 
RF pulse and without a 180° RF rephrasing pulse. The flip angle is usually below 90°. After 
the pulse, a positive gradient is applied, rephasing the net magnetization. Here the echo is 
not compensating for dephasing caused by static field inhomogeneities or transversal re-
laxation. Therefore, the decay of the echo is T2* dependent [59]. The benefit of this se-
quence is its faster acquisition time, which can be realized due to the lower FA, resulting in 
a possibly shorter TR. One limitation is that for this sequence, there is always a T2* effect 
despite T1 weighted sequence parameters. 
2.5.6 TISSUE CONTRASTS 
Simply by varying the sequence parameters, different image contrasts—which represent 
the tissue specific properties—can be generated. Notably, these contrasts provide qualita-
tive information about the tissue. 
Proton density weighted image: High signal intensity represents a high proportion of water 
protons in the corresponding volume. For this contrast, relaxation times should have only 
a minimal influence on the image contrast. This is achieved with a spin echo sequence with 
short TE and a long TR. 
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T1-weighted image: This contrast is mainly based on the different longitudinal relaxation 
times of biological tissue, where high signal intensity stands for a short T1 time. This is 
achieved with a short TE and short TR. 
T2-weighted image: This contrast is dominated by the transversal relaxation times of bio-
logical tissue. High signal intensity in the image results from a long T2-time. This is 
achieved with a long TE and a long TR. 
2.5.7 T1 QUANTIFICATION 
For some applications, qualitative information from T1 weighted images is not sufficient 
and a T1 quantification is necessary. In this work, the T1 quantification was based on a var-
iable flip angle method [53].  
Variable flip angle 
A method for T1 determination is the variable flip angle (VFA) method. This method is 
based on the FLASH signal equation[58]: 
 𝑆 = 𝑆0 ∗ sin(𝛼) ∗
1−𝐸1
1−cos(𝛼)∗𝐸1
∗ 𝐸2 
13 
Where 𝐸1 = exp(−𝑇𝑅 𝑇1⁄ ) and 𝐸2 = exp(−𝑇𝐸 𝑇2
∗⁄ ). For T1 determination, typically two or 
more FA α are used in a range between 2° and 30° [60]. Measuring the signal amplitude for 
at least two different flip angles, the T1 relaxation time can be calculated with equation 13. 
For applications requiring a high temporal resolution, the acquisition time can be acceler-
ated by combining a baseline acquisition with two flip angles, which is followed by repeat-
ed measurements with only one flip angle. This method was introduced by Brookes et al. 
in 1996 [61], and was improved by Dietrich et al. [62] with multiple flip angles serving as 
the baseline for calculating S0. With Sdyn, the single flip angle αdyn, and the known S0 from 
the baseline measurement, the value for T1 can be determined with: 
 𝐸1,𝑑𝑦𝑛 =
𝑆0𝐸2 sin(𝛼𝑑𝑦𝑛)−𝑆𝑑𝑦𝑛
𝑆0𝐸2 sin(𝛼𝑑𝑦𝑛)−𝑆𝑑𝑦𝑛 cos(𝛼𝑑𝑦𝑛)
 
 ≈
𝑆0 sin(𝛼𝑑𝑦𝑛)−𝑆𝑑𝑦𝑛
𝑆0 sin(𝛼𝑑𝑦𝑛)−𝑆𝑑𝑦𝑛 cos(𝛼𝑑𝑦𝑛)
 
14 
The resulting approximation is based on neglecting the T2* dependence. 
Basics 24 
 
For the dynamic measurement from time-resolved data, contrast-enhanced MRI usually 
employs 2D or 3D sequences with a spoiled gradient echo readout. The use of 3D acquisi-
tion provides different benefits compared to a 2D measurement. For example, with a 3D 
acquisition, coverage of a whole volume is possible without slice spacing.  
2.5.8 NON-INVASIVE TEMPERATURE MEASUREMENT 
Non-invasive temperature measurement by MRI is a tool that controls mild HT in biologi-
cal tissue. There are numerous parameters in MR-Imaging that are temperature-sensitive. 
Temperature-sensitive parameters include: magnetization M0, T1-relaxation time, 
T2-relaxation time, diffusion, and proton resonance frequency. Only the T1-relaxation time 
and the proton frequency allow a sufficient acquisition time, a good signal to noise ratio, 
and a good spatial resolution during MR-Imaging [63].  
T1-relaxation temperature dependency 
Bloembergen et al. demonstrated the temperature dependence of the T1-relaxation time in 
1948 [64], and in 1984, this dependence was investigated for non-invasive thermometry 
in MRI[65]. As described in chapter 2.5.3, spin-lattice relaxation in biological tissues re-
sults from dipolar interactions of macromolecules and water molecules, which appear 
from their relative movement to each other. These motions are temperature-dependent, 
and are thus reflected in changes in the spin-lattice relaxation time T1 [66]. The variation 
of the T1 relaxation time of water protons can be described with [67]: 
 𝑻𝟏 ∝ 𝒆−𝑬𝜶/𝒌𝑻 
15 
where Eα is the activation energy for self-diffusion of water, k is the Boltzmann constant, 
and T is the absolute temperature. From the change in the spin-spin-lattice relaxation and 
the temperature change, a linear relationship can be assumed for small physiological tem-
perature changes [63]: 
 𝑻𝟏(𝑻) = 𝑻𝟏(𝑻𝒓𝒆𝒇) + 𝒎 ∗ (𝑻 − 𝑻𝒓𝒆𝒇) 
16 
where Tref is the reference temperature and T the absolute temperature. The dependency 
m = dT1/dT must be empirically determined for every tissue. At an initial approximation, a 
1%/°C T1-change can be expected [63]. This approximation is not valid for large tempera-
ture changes and tissue modification, which occur during, for example, coagulation or oth-
er pathological tissue changes. 
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It is also possible to calculate the temperature change with the T1 weighted signal change 
caused by the T1-change. For this method, the change in the M0 must be determined or 
neglected, which yields greater inaccuracies and is not commonly used for quantitative 
temperature mapping [63]. 
Temperature-induced frequency shift 
After Fourier transformation (chapter 2.5.4) of the MRI-signal, there are three kinds of 
data sets reconstructed from the raw data: real data, the magnitude data, and the phase 
data. This phase information can be used to calculate a temperature change between two 
different time points. That temperature dependency of the proton resonance frequency 
shift was first observed by Hindman [68] and was implemented for MRI temperature-
mapping by De Poorter et al. [69,70].  
Among other factors, the lamor frequency of a nucleus is determined by the local magnetic 
field, expressed by [63]: 
 𝝎 = 𝜸𝑩𝟎(𝟏 − 𝒔) 
17 
where s is the shielding constant. This shielding constant, which differs with the chemical 
compound, is used e. g. in MR-spectroscopy. Furthermore, this shielding constant is tem-
perature-dependent. The 1H-nucleus is shielded by electrons. For Water (H2O) the elec-
trons are bound in hydrogen bonds. This yields a smaller shielding compared to the 
1H-nucleus. An increase in temperature leads to a destabilization of the hydrogen bonds, 
therefore the electrons are less “tied” in these bonds. This ensures better shielding of the 
1H-nucleus and a decrease in the Larmor frequency. Frequency changes cause a phase dif-
ference in the acquired signal (Figure 7), 
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Figure 7: Phase value  for temperature baseline measurement T0 (blue/ dotted line) and 
follow up measurement T(t) (red/ continuous line). 
which can be used to calculate temperature change with: 
 ∆𝑻(𝒕) =
𝝓(𝑻(𝒕))−𝝓(𝑻𝟎)
𝜸𝜶𝑩𝟎𝑻𝑬
 
18 
where γ is the gyromagnetic ratio (42.567 MHz T⁄  for 1H [53]), α is the PRF change coeffi-
cient (-0.01 ppm/°C), B0 is the magnetic field strength and TE is the echo time [63]. 
2.5.9 DYNAMIC CONTRAST-ENHANCED MR-IMAGING 
Medical application of MR-Imaging can be enhanced by the application of contrast 
agents (CA). In the context of MR-Imaging, the CA is not directly visible; instead, the effect 
of the contrast agent on the relaxation of surrounding nuclear spins is observable. The CA 
influences the relaxation times T1, T2 and T2* in its direct environment. Different tissues 
are affected differently depending on the magnetic properties of the contrast agents. The 
image contrast can be changed with CA to provide additional information about the tissue. 
For clinical use, contrast agents are most commonly based on gadolinium (Gd), which 
shortens the T1 relaxation time. This results in increased signal intensity in a T1-weighted 
image. Gadolinium-based contrast agents reduce beside T1 also the T2 relaxation times. In 
T1-weighted scans, change of T2 relaxation time is only visible at high Gd concentrations of 
several mM [71,72]. Dynamic contrast-enhanced MR-Imaging is used to determine ancil-
lary information about the examined tissue, such as hemodynamic parameters. 
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The Fundamental effect of CA-TSL 
Encapsulating contrast agents in TSL alters signal performance in comparison to free CA. 
The CA-TSL used in this study has a low r1 as long as the CA is encapsulated in the TSL at 
temperatures below Tm. This condition is due to the limitation in water exchange through 
the membrane resulting in a limitation of the dipolar relaxation process [73]. Limiting the 
dipolar relaxation process then results in little T1 variation in the presence of the TSL, and 
a low signal change in a T1-weighted image. After heating up the liposomes, the mem-
branes of the TSL becomes more permeable to water at Tm, and the water exchange 
through the membrane increases until the CA is released above Tm. CA release results in a 
decrease of T1 and a signal increase; as the temperature initially increases, these effects 
are instigated by water exchange. At yet higher temperatures, the CA is released as de-
scribed in figure 8. 
 
Figure 8: Principle of T1 and signal change for CA-TSL in water during temperature increase. 
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3. COMPARISON AND VALIDATION OF HEATING METHODS 
Markedly diverse localized heating methods have been applied in preclinical animal stud-
ies for various drug delivery systems and related studies. This diversity prevents proper 
comparison of experimental results, such as homogeneity of the heating and the effective-
ness of drug uptake in the tumor that these parameters warrant due to their role in the 
therapeutic response. Heating methods can be non-invasive—such as water bath heating 
[74–77], electric heating coils [14,78], heating lamps [20,79–81], laser light [82], focused 
ultrasound [83–85], and radio frequency [30]—or as invasive as a heat pipe through the 
tumor [26].  
To investigate mild HT in combination with TSL in a small animal model, a newly devel-
oped MRI-compatible laser light applicator was built and compared to previously popular 
methods for inducing mild HT in experimental setups. The laser light applicator was also 
tested in order to validate its use in the MRI study in the second part of the thesis.  
In this study described in chapter 3, the characteristics and the comparability of three dif-
ferent methods for mild HT for subcutaneous tumors in small animal models were investi-
gated. Mild HT was applied to a subcutaneous syngeneic rat tumor using either a water 
bath, a cold light lamp, or an infrared laser. In light of the rising popularity of MRI-guided 
treatments, the laser applicator was built to be MRI-compatible, and was then compared 
to the other heating methods.  
The new method may therefore offer a more local heat application than the regional heat-
ing achievable with water baths, in the context of MRI and CA-TSL [74,86]. The new meth-
od is also easier to implement in an MRI birdcage coil than a water bath or a heating lamp. 
In this work, the effectiveness of mild HT-induced drug release from TSL in small animals 
with subcutaneous implanted syngeneic tumors was investigated with different preclinical 
HT methods. Therefore, widely applied HT methods such as cold light lamp and water bath 
were characterized and compared to HT-induced by a newly developed MR-compatible 
laser-based device. 
Parts of this section (Chapter 3) are also published in the Journal Of Controlled Release by 
Willerding et al. [87]. 
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3.1 EXPERIMENTAL SETUP 
The comparability of temperature homogeneity and the effectiveness of drug uptake in 
combination with TSL in the tumor were examined. A water bath, a cold light lamp, and a 
newly developed infrared laser light applicator were used for heating. To assess the heat-
ing methods in different tumor volumes, two separate groups of tumor volumes 
(0.5 cm3 < V < 1.0 cm3 and 2.0 cm3 < V < 3.0 cm3) were investigated.  
Different parameters were investigated: heat distribution and drug concentration in the 
heated tumor, and drug concentration in the unheated tumor. Furthermore, a pharmaco-
kinetic (PK) study was performed. Data were analyzed with statistics software (SPSS Sta-
tistics V22, IBM, Germany). 
After reaching the expected tumor size, experiments were carried out in accordance with 
the protocols described further on. 
Tumor-bearing rats were assigned randomly to one of the three heating methods and one 
of the two tumor size groups. This results in six different groups, each with three animals. 
After one tumor reached the target tumor size, this tumor was defined as the “heated tu-
mor”. Minimum tumor size for both tumors was 0.1 cm3. Both of the tumors were shaved, 
and the tumor probes were implanted as described below (chapter 3.2.3).  
For water bath heating, the leg of the heated tumor was wrapped in plastic foil to prevent 
swelling of the skin caused by warm water. For lamp heating, the surrounding skin of the 
tumor was protected with cotton wool. Due to the Gaussian distribution of optical power 
in the laser beam as described above (chapter 3.2.4), the laser light beam was adjusted 
10 mm larger in diameter than the tumor. 
After animal preparation, the heating began. DOX-TSL (2 mg/kg) were injected after min-
imum target temperature – 40 °C – was reached in each of the temperature probes. 60 min 
after injection the heating device was turned off—or the leg was taken out of the water 
bath—and the tumor was cooled down immediately with a cooling pack. For PK, capillary 
blood (200 µl) was taken before heating, 2 min and 60 min after injection with a heparin-
coated tube (Microvette 200, Sarstedt AG & Co., Nürnbrecht, Germany); the sample was 
centrifuged and frozen until HPLC DOX measurement. After letting the tumor cool down to 
normal temperature, the rats were euthanatized during deep inhalation anesthesia by 
injection of pentobarbital.  
For drug uptake analysis in tumor tissue, the heated tumor was removed and bisected 
parallel to the body axis. The unheated tumor was removed completely. To exclude possi-
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ble influence of the heating mattress on the PK and the drug uptake in the tumor, for every 
heating device, one muscle tissue sample from the abdominal wall was taken. 
3.2 METHODS 
3.2.1 PREPARATION OF LIPOSOMES 
Lipid composition of all TSL formulations was DPPC/DSPC/DPPG2 50/20/30 (mol/mol) 
(DPPG2-TSL). TSL encapsulating either 300 mM citrate pH 4.0 or 250 mM Gd-DTPA-BMA, 
pH 7.4 were prepared according to the lipid film hydration and extrusion method de-
scribed in detail by Hossann et al. in 2010 and 2013 [18,88]. DOX was actively loaded to 
the citrate containing liposomes [18]. 
All preparations were performed as aforementioned [17,18,88]. In brief, the hydrodynam-
ic diameter (z average) size intensity distribution plot and zeta potential were measured 
by DLS (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, United Kingdom). The 
instrument was calibrated with a size standard (NanosphereTM, 125 nm, Thermo Fisher 
Scientific, Waltham, MA, USA). Phospholipid composition and shelf life was measured with 
thin layer chromatography (TLC). TLC plates were developed with chloro-
form/methanol/acetic acid (97.5%)/water 100:60:10:5 (vol/vol) to separately detect 
phosphatidylcholines (DPPC, DSPC), DPPG2, and their decomposition products (Lyso-PC, 
Lyso-PG2). A lipid standard containing DPPC, DPPG2, and lyso-phosphatidylcholine was 
applied in every TLC run to check the separation quality. Phospholipid concentration was 
quantified by a phosphate assay using a 1 g/l phosphate solution (Merck KGaA, Darmstadt, 
Germany) as reference standard. DOX concentration was measured by fluorescence spec-
troscopy (Varian Cary Eclipse) after disruption of the liposomes with Triton X-100. Com-
mercially available non-thermosensitive PEGylated liposomal DOX (Caelyx®, Jannsen-Cilag 
GmbH, Neuss, Germany) and non-liposomal DOX (Adriplastin®, Pharmacia GmbH, Karls-
ruhe, Germany) were used as reference standards. The concentration of gadodiamide was 
quantified by inductively-coupled plasma atomic emission spectroscopy (ICP-AES) using a 
gadolinium ICP standard solution (Merck KGaA, Darmstadt, Germany) as reference stand-
ard. The thermosensitivity of each preparation was shown in vitro by measuring the tem-
perature-dependent release profile of DOX and gadodiamide with fluorescence spectros-
copy (Cary Eclipse, Varian Inc., Palo Alto, CA, USA) and a 0.47 T NMR-analyzer (Minispec 
NMS120, Bruker BioSpin GmbH, Rheinstetten, Germany), respectively. The liposomes had 
a phase transition temperature (Tm) of 40 °C. The characterization of DOX liposomes is 
given in supplementary table  1, 2. 
Comparison and validation of heating methods 31 
 
For the comparison and validation of heating methods, only DOX-TSL were used. CA-TSL 
were used for therapy monitoring in later experiments (chapter 4). 
3.2.2 ANIMAL MODEL 
For animal experiments, the syngeneic BN175 cell line was used (kindly provided by Timo 
ten Hagen, Erasmus MF, Rotterdam). Cells were grown in RPMI 1640 medium (Biochrom 
AG, Berlin, Germany) supplemented with 10 % fetal calf serum (FCS) (vol/vol), 100 U/ml 
penicillin and 100 µg/ml streptomycin, respectively. Cells were cultured at 37°C in a hu-
midified atmosphere of 95 % air and 5 % CO2.  
Experiments were performed in accordance with approved protocols (Regierung von 
Oberbayern, CaNo. 55.22.1.54-2532.3-21-11). The experiments were performed under 
anesthesia (isofluran 2-5 % and oxygen 1.5 l/min) administered with an isofluran evapo-
rator (Vapor 19.3, Dräger, Germany). For Tumor growth 1.5x106 / 50 µl BN175 cells were 
injected in both hind legs. Tumor growth was recorded in three plains 
(length = a; width = b; height = c) by caliper measurements. The volume was calculated 
using an ellipsoid approximation (Equation 19). Tumor growth was measured every sec-
ond day. 
𝑉 =
𝜋
6
∗ 𝑎 ∗ 𝑏 ∗ 𝑐 
19 
Injection of tumor cells was used, because for tumors with a volume larger than 2 cm³ and 
the rapid tumor growth a re-opening of the lesion from an implantation cannot be exclud-
ed. 
3.2.3 TEMPERATURE MEASUREMENTS 
Temperature was measured with a temperature data-logger (K204, Voltcraft, Germany). 
To assess an overview of the temperature distribution in the tumor, three temperature 
probes were implanted in the tumor at a pre-defined depth. For accurate insertion of the 
temperature probes, three cannulas (20G needle, BD MicrolanceTM, Germany) were im-
planted parallel to the body axis, and were removed after insertion of the probes. Specific 
depths were assigned by scale paper to ensure an approximated depth of 2-3 mm for the 
lateral, 5-6 mm for the central, and 7-10 mm for the medial probe. To assess the accurate 
depth of every tumor probe, photographs were taken with scale paper prior to removal of 
the cannulas. The distance to the skin was measured with an image post-processing pro-
gram (GIMP 2.8, open source). Measurements were performed twice, on two different 
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photographs from different angles to reduce errors. The procedure of measurement is 
shown in Figure 9. 
 
Figure 9: Procedure of measurements for probe depth, drawn lines marked the estimated 
position of the probe [87]. 
From the temperature data, the equivalent time at 43 °C (CEM43 °C) was calculated with 
equation 20 [89]: 
CEM43°C = ∑ R
(43−?̅?)∆t
t=final
t=0
 
20 
where 𝑇 is the average temperature during time ∆t. For temperatures above 43°C R = 0.5 
and for temperatures below 43°C R = 0.25. CEM43°C considers varying temperatures in tis-
sue – time-temperature relationship – and determines the equivalent heating time at 43 °C 
to attain a comparable effect on the tissue. CEM43°C was calculated as mean value for each 
temperature probe. Furthermore, the temperature exceeded by 10 %, 50 %, and 90 % of 
the measurement points were determined (T10, T50, T90). This temperature representation 
is less influenced by outliers and is commonly used in clinical HT. 
3.2.4 LASER LIGHT APPLICATOR 
For adequate local heating of the tumor in the MRI, a novel non-invasive HT applicator 
was needed. The engineering drawings were created with a computer-aided design (CAD) 
program (Solid Works ST5, Siemens Industry Software GmbH & Co. KG, Germany) and are 
presented in the supplement chapter 6.2.3. 
Requirements 
Requirements for the applicator were as follows: the applicator should be able to locally 
heat up a subcutaneous tumor with a size up to 2,5 cm³ homogenously. It must induce a 
minimal tumor temperature level of 40 °C and a maximum temperature of 44 °C. In addi-
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tion, it must be MRI-compatible and –save. This means that must be no artifacts induced 
by the applicator, and no use of para-, ferromagnetic or electric conductive materials. It 
should fit into the lateral part of a dedicated wrist coil, beside the animal. Thus, it must 
have a maximum dimension of 35 mm in diameter. Because of the open design of the wrist 
coil, a maximum length was not given. Laser light should induce heating and source power 
had to be controllable from outside of the RF cabin. The heated volume should be adjusta-
ble to tumor size. In case of a defect or a change in requirements, all components of the 
applicator should be exchangeable.  
Implementation 
As power source, a 940 nm laser (Medilas D940, Dornier MedTech, Germany) was availa-
ble. This wavelength in the NIR promises a high penetration depth of the light. The laser 
light was guided to the applicator with a glass fiber (10 m, 600 µm). The laser beam was 
adjusted using two lenses: one convex lens (focal length 5 mm) used as collimator and one 
concave lens (-10 mm) for beam expansion. A deflecting prism (25 mm Fused Silica Right 
Angle Prism Al & AR Coated, Edmund Optics GmbH, Germany) was used to significantly 
reduce the overall height of the applicator to fit into the wrist coil. An aluminized coated 
hypotenuse ensured a total reflection of the laser beam and protected the prism surface 
against damage during handling. The beam diameter was adjustable by controlling the 
distance between lens system and prism (Figure 10).  
 
Figure 10: Half section of HT applicator with beam path (red lines) for a) small or b) large 
beam; ① convex lens; ② concave lens; ③ deflecting prism; green  outer tube; black 
inner tube. 
The applicator consisted of six elements, which were divided into two assemblies, the 
housing and the lens system. The housing was made from two tubes. The outer tube (OT) 
held the prism and the inner tube (IT) held the second assembly. To guarantee the mova-
bility of the tubes against each other, an interference fit (𝑑ℎ9
𝐻8) was used. A slot in the OT 
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and a thread in the IT were made to secure the tube against rotation and to fix the lens 
system inside the IT with a screw, while allowing a shift of 60 mm in the axial direction. 
Lenses were installed in the second assembly, which consisted of three parts: the main 
part that fixed the glass fiber and the collimation lens; the middle part, which defines the 
distance between the collimation and concave lenses; and the cover that fixes the concave 
lens and the middle part to the main part. To guarantee MR-safety and compatibility, the 
housing and mount for the lenses were composed of plastics (Polyethylene). To facilitate 
replacement of single parts of the applicator, all joints were fixed with nylon screws. The 
prism was attached with a double-sided adhesive tape so the prism can be removed when 
necessary. Details and exact dimension are presented in the engineering drawings (chap-
ter 6.2.3). 
Laser power must be manipulated manually either with laser power itself, or by modulat-
ing the laser beam with on and off time periods. Laser power could be set to 1 W – 60 W 
(Watt) in steps of 1 W while the applicator could handle 10 W. The laser could be modu-
lated with an increment of 0.01 s (0.01 s < t < 0.1 s) and an increment of 0.1 s (t > 0.1 s).  
Preliminary tests revealed an insufficient heating of the base of the tumor along with a 
high temperature on the surface of the tumor with continuous wave heating (CW). There-
fore, all following experiments were performed using a rectangle-shaped modulated laser 
power with: on time 0.05 s – 0.50 s; off time 0.05 s – 0.50 s. 
For following experiments, the intensity of a TEM00 laser beam is described most closely 
by a Gaussian distribution [90]: 
𝐼(𝑟) = 𝐼0 ∗ 𝑒
−2𝑟2
𝑤2  
21 
Where I0 is the maximum intensity on the optical axis, r is the distance from this axis. 
Beam width is described as w, where the laser beam has 1
𝑒2⁄
 of the maximum intensity I0. 
Thus w of the laser beam had to be ~ 1.3 times of the tumor diameter to provide ~ 40 % of 
I0 to the outer rim of the tumor. 
3.2.5 WATER BATH 
Many study groups use a temperature controlled water bath for mild HT optional with 
thermosensitive liposomes [74,85]. Therefore, a water bath was used as a reference meth-
od for comparison with the new laser applicator. 
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Requirements 
Like the laser light applicator, the water bath had to be able to regionally, homogenously 
heat a subcutaneous tumor with a size of up to 2,5 cm³. It also had to induce a tumor tem-
perature of minimum 40 °C, with a maximum temperature of 44 °C. The rat body needed 
to be protected from the heat of the water bath. Water temperature had to be controllable 
in a range from 39 °C to 46 °C. 
Implementation 
A water bath served as a heating source and water reservoir (JB Aqua 26L, Gran Instru-
ments, United Kingdom). The temperature was manually controllable and the temperature 
was measured with a temperature probe (temperature data-logger, Voltcraft K204; tem-
perature probe GTF 101; ATP Messtechnik GmbH, Germany). The rat was separated from 
water with a plastic plate (PMMA, Polymethylmethacrylate) and insulated from the heat 
by a polystyrene sheet (20 cm x 20cm x 1 cm). Both the plastic plate and the polystyrene 
sheet had holes for submersion of the tumor-bearing leg into the water bath. For this set-
up, a plastic foil was applied around the heated leg to prevent swelling of the skin due to 
the warm water. The setup is shown in Figure 11. For the experiment, water was warmed 
up to 42°C before the tumor bearing leg was inserted into the water. Temperature was 
controlled either by raising the temperature or by cooling with cold water. 
  
Figure 11: Illustration of experimental setup for water bath hyperthermia with polystyrene 
sheet and thermometer. 
3.2.6 LAMP 
In previous experiments [20], a cold light lamp was used to induce local HT in a subcuta-
neous tumor model. To facilitate comparability between the laser light applicator and the 
lamp, experiments were repeated under the same experimental setup as the laser light 
experiments.  
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Requirements 
Like the laser light applicator, the lamp should be able to locally heat up a subcutaneous 
tumor with a size up to 2.5 cm³ homogenously. It also had to induce a tumor temperature 
of minimum 40 °C and with a maximum temperature of 44 °C. 
Implementation 
To induce local mild HT a cold light lamp (Optich PL 2000, Photonic Optische Geräte GmbH 
& Co. KG, Austria) was used. The lamp had one light source with two fiberglass gooseneck 
lights. To prevent the goosenecks from overheating, an infrared absorption filter 
(Supplementary figure 1) was applied, resulting in a light spectrum, which is not optimal 
for a high penetration depth. The light power was controlled manually by a rotary knob.  
 
Figure 12: Experimental setup for mild HT with cold light lamp, heating mattress and ther-
mometer. 
3.2.7 DOX QUANTIFICATION IN PHARMACOKINETIC STUDIES 
Concentrations of DOX of plasma and tissue samples were quantified with high perfor-
mance liquid chromatography (HPLC). Prior to analysis, the analyte was extracted from 
samples through a modified liquid extraction protocol [91]. 
Plasma samples (50 µl) were diluted to 1 ml using phosphate-buffered saline. 100 µl in-
ternal standard (daunorubicin, 10 µg/ml) and 10 ml dichloromethane / isopropyl alcohol 
9:1 (vol/vol) were added to each sample. Subsequently, the sample was vigorously mixed 
and centrifuged, and the organic phase was transferred to a fresh tube. Under a steady 
stream of nitrogen at 40 °C, the extract was freed from the solvent. The sediment was dis-
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solved in 1 ml 80 mM potassium dihydrogenphosphate / acetonitrile 73:27 (vol/vol) and 
transferred to HPLC injection tubes after centrifugation. 
Tissue samples (100 mg) were added to 1.5 ml methanol / water 2:1 (vol/vol) and 100 µl 
internal standard in 2 ml Eppendorf tubes. Homogenization was performed with tungsten 
carbide beads in a TissueLyser (Qiagen GmbH, Hilden, Germany) at 30 Hz for 5 min. To 
each sample, 200 µl silver nitrate 33% (weight/volume) was added and the sample was 
subsequently incubated for 10 min on ice to release DOX from its binding to DNA [92]. The 
samples were transferred to 10 ml centrifuge tubes and 5 ml chloroform / isopropyl alco-
hol 2:1 (vol/vol) was added. After vigorous mixing and centrifugation, the organic phase 
was transferred to a fresh tube, freed from solvent, and processed as described above for 
plasma samples. 
Samples were measured with a Waters HPLC system (515 HPLC pump, 717plus au-
tosampler, 470 fluorescence detector). Fluorescence detection was performed with an 
excitation wavelength of 480 nm and an emission wavelength of 560 nm. The runs were 
carried out on a C18 column (250 mm x 4.6 mm internal diameter, 5 µm particle size; 125 
Å pore size) from Phenomenex Ltd., Germany. 50 µl per sample was injected and eluted 
with an isocratic flow of 1 ml/min using 80 mM potassium dihydrogenphosphate / ace-
tonitrile 73:27 (vol/vol) as mobile phase. Adriblastin® was used as reference standard. 
3.2.8 STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS V22 (IBM, Germany). For correlation analy-
sis, the concept of bivariate correlation according to Pearson was used [93]. Differences 
between two data sets were tested using two-tailed students t-test. P-values were consid-
ered to be (highly) significant if they were less than or equal to 0.05 (0.01). 
3.3 RESULTS 
18 animals were treated successfully. HPLC analysis was performed on 54 tumor samples, 
3 muscle samples and 54 plasma samples for DOX-quantification. Red skin was observed 
in 5 animals (2x using the lamp with small tumor, 1 x laser large tumors, 1 x laser small 
tumors). 
3.3.1 TUMOR SIZE AND POSITION OF TEMPERATURE PROBES 
The median size of the tumors was 1.0 cm3, with a standard deviation of 0.1 cm³ for small 
tumors and 2.2 cm³ ± 0.2 cm³ for larger tumors. The reference tumors had a median vol-
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ume of 1.2 cm³ ± 0.8 cm³ (mean ± SD) across all experiments. The average depths of the 
temperature probes were 8.6 mm ± 1.4 mm for the medial, 5.6 mm ± 1.1 mm for the cen-
tral, and 2.8 mm ± 0.7 mm for the lateral probe. The weight ratio between the lateral and 
medial tumor parts for all experiments was 1.02 ± 0.52. 
3.3.2 TEMPERATURE DISTRIBUTION 
In all experiments, the requested minimum mean temperature of 40°C was achieved for all 
three temperature probes in all treatment groups. The highest temperature was always 
measured in the lateral part of the tumor, decreasing with increasing tissue depth inde-
pendent of the heating method. The highest temperature for a single animal (44.3 °C) was 
achieved with the laser light applicator in the lateral part of the larger tumors, decreasing 
to 40.0 °C in the medial part. For visualization, all temperature values are plotted in Fig-
ure 13.  
 
Figure 13: Boxplot of the temperature values for all experiments and temperature probes 
differentiated between heating method and smaller (1.0 ± 0.1 cm³) or larger tumor volumes 
(2.2 ± 0.2 cm³). 
For each heating experiment, temperature data from the three probes were used to assess 
the temperature gradient inside the tumor (Table 3). The lowest temperature gradient 
was found during the water bath heating, with -0.1 °C/mm in the small tumor 
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and -0.2 °C/mm in the large tumor. The highest temperature gradient in the small tumors 
was recorded while using the lamp, and the laser resulted in the highest temperature gra-
dient of the large tumors (-0.3 °C/mm). For the water bath and the laser, temperature gra-
dients were steeper in the larger tumors, whereas in the lamp experiments, the mean gra-
dient was steeper for smaller tumors (Table 3).  
Method Tumor size 
Temperature 
gradient 
[°C/mm] 
SD [°C/mm] 
Lamp 
large 0.25 ±0.11 
small 0.54 ±0.33 
Laser 
large 0.47 ±0.34 
small 0.48 ±0.29 
Water bath 
large 0.20 ±0.07 
small 0.10 ±0.11 
Table 3: Temperature gradients with standard deviation for the different experimental 
groups. 
The efficacy of heating was investigated by calculating T10, T50, T90 and CEM43°C (Table 4). 
The highest T10 of 44.4°C for a single experiment was obtained in a large tumor heated by 
the laser. The smallest T90 of 39.9 °C was achieved in a small tumor with the lamp.  
Heating 
method 
Tumor 
size 
T90 [°C] T50 [°C] T10 [°C] CEM43°C [min] 
Lamp 
small 40.2 ± 0.4 41.7 ± 1.4 43.3 ± 1.2 36.4 ± 34.0 
large 40.2 ± 0.2 41.0 ± 0.5 42.4 ± 0.0 10.5 ±  0.7 
Laser 
small 40.3 ± 0.4 41.5 ± 0.6 42.6 ± 0.9 16.4 ± 13.5 
large 40.1 ± 0.2 41.7 ± 0.7 43.1 ± 1.2 29.5 ± 26.5 
Water bath 
small 40.6 ± 0.2 41.2 ± 0.2 41.6 ± 0.1 5.2 ±  0.6 
large 40.6 ± 0.3 41.7 ± 0.4 42.1 ± 0.4 9.9 ±  5.2 
Table 4: T90, T50, T10 and CEM43°C data for the whole tumor with standard deviation for every 
experimental group. 
CEM43°C was calculated with equation 20 for every temperature probe, and results are dis-
played with corresponding tissue damage signs in table 5. For a single probe, the highest 
value reached was 152 CEM43°C, from a laser experiment with a large tumor. Over 80 
CEM43°C were reached in three experiments: two lamp experiments with a small tumor and 
one laser experiment with a large tumor. Four animals exhibited redness of the skin above 
the heated tumor after mild HT. These animals had a CEM43 °C of 83.4 min, 115.8 min, 
152.0 min and 77.0 min measured in the lateral tumor probe. 
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          Equivalent minutes for 43 °C (CEM43°C) 
Heating Tumor Animal Tumor Tumor DOX medial central lateral Mean 
size no. volume (cm³) concentration [ng/mg] (min) (min) (min) (min) 
La
m
p
 
large 
N20 2.0 14.2 1.4 2.6 26.2 10.1 ± 14.0 
N23 2.2 13.5 1.1 3.7 25.3 10.0 ± 13.3 
V33 2.4 18.7 2.6 12.3 19.1 11.3 ± 8.3 
small 
V23 0.8 23.3 1.0 3.9 83.4 29.5 ± 46.8 
V36 1.0 22.6 3.2 2.6 13.2 6.3 ± 6.0 
V37 1.0 23.4 1.7 102.3 115.8 73.3 ± 62.4 
La
se
r 
large 
N44 2.1 7.0 2.9 2.8 13.3 6.3 ± 6.0 
V27 2.2 6.1 0.9 22.5 152.0 58.4 ± 81.8 
V39 2.1 18.0 1.0 16.2 53.5 23.8 ± 26.9 
small 
N47 1.0 23.3 1.0 16.7 77.0 31.5 ± 40.1 
V21 0.9 19.7 2.6 3.9 10.0 5.5 ± 4.0 
V29 1.0 14.8 1.2 7.7 27.2 12.0 ± 13.4 
w
at
er
 b
at
h
 large 
V26 2.1 4.5 2.9 23.5 20.8 15.7 ± 11.2 
V32 2.7 4.8 1.6 9.2 14.3 8.3 ± 6.4 
V35 2.1 4.3 2.7 6.1 8.2 5.7 ± 2.8 
small 
V24 1.0 6.1 4.8 5.1 6.4 5.4 ± 0.8 
V28 0.9 9.3 4.4 6.3 6.1 5.6 ± 1.1 
V38 0.9 24.5 1.9 4.5 7.0 4.5 ± 2.6 
Table 5: CEM43°C for every experiment and temperature probe. Grey shaded areas imply an-
imals with red skin after therapy caused by heating. 
3.3.3 DRUG DISTRIBUTION 
The mean DOX concentration in the three not-heated muscle tissue samples was 
0.5 ± 0.1 ng/mg. The mean DOX concentration in the reference tumor averaged over all 
experiments was 1.2 ± 0.4 ng/mg. For the large treated tumors the DOX concentration in 
the reference tumor was 1.0 ± 0.3 ng/mg and for the small treated tumors it was 
1.4 ± 0.4 ng/mg (p < 0.05). The highest DOX concentration (23.1 ± 0.4 ng/mg) was found 
in the animals with small tumors heated by lamp. The lowest DOX concentration was 
found in the tumors heated with the water bath (4.5 ± 0.3 ng/mg). Independently of the 
heating method, the DOX concentration was higher in smaller tumors compared to larger 
tumors. Concentration ratio in the heated tumor was 4 times up to 17 times the DOX con-
centration of the not-heated tumor dependent on the heating method (Table 6). All meas-
ured and calculated drug concentrations are shown in supplementary table 3. 
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Tumor with HT  
(ng/mg) ± SD 
T. without HT 
(ng/mg) 
DOX ratio 
HT Size Lateral part Medial part Mean   
lateral 
/medial 
with/  
without HT 
Lamp 
small 24.2 (± 0.9) 22.0 (± 1.3) 23.1 (± 0.4) 1.4 (± 0.5) 1.1 17 
large 23.4 (± 4.6) 7.9 (± 6.4) 15.4 (± 2.8) 1.0 (± 0.3) 3.0 15 
Laser 
small 24.4 (± 6.4) 12.8 (± 1.7) 19.3 (± 4.2) 1.3 (± 0.5) 1.9 15 
large 11.5 (± 9.8) 9.2 (± 4.8) 10.4 (± 6.6) 0.8 (± 0.2) 1.3 13 
Water 
bath 
small 11.8 (± 8.1) 14.5 (± 10.9) 13.3 (± 9.9) 1.4 (± 0.4) 0.8 10 
large 4.1 (± 1.2) 5.2 (± 0.5) 4.5 (± 0.3) 1.1 (± 0.5) 0.8 4 
Table 6: Mean and standard deviation of DOX concentrations for the two tumor parts and 
their weighted sum of the tumors exposed to HT in comparison to the reference tumors not 
exposed to HT. For comparison, ratios of DOX concentration were calculated in the heated 
tumor comparing lateral and medial tumor parts or tumor exposed with and without HT. 
The DOX concentration in the lateral and medial tumor sections of the heated tumors were 
evaluated in relation to the applied heating method (Figure 14) and relative to the total 
tumor size. The smallest concentration ratio between the medial and the lateral tumor 
part was found for the water bath heating with 0.8 for the small and large tumors, respec-
tively. For the laser heating the drug ratios were 1.8 and 1.5, whereas for the lamp heating 
the ratios were 1.1 and 2.7, respectively.  
 
Figure 14: Boxplot for the DOX concentration for different tumor parts: The reference tumor 
(blank), lateral (hatched), the whole tumor (dotted) and the medial tumor (checker) part for 
all experiments  
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There was no significant correlation (p > 0.05) between the medial temperature, central 
temperature, lateral temperature, T90, T50, T10 and CEM43°C compared to the DOX concen-
tration in the lateral tumor half, the medial tumor half or the whole tumor for all experi-
ments (Table 7). 
  
medial 
tempera-
ture [°C] 
central 
tempera-
ture [°C] 
lateral  
temperature 
[°C] 
mean  
temperature 
[°C] 
T90 
[°C] 
T50 
[°C] 
T10 
[°C] 
lateral  
tumor 
tissue 
[ng/mg] 
-0.311 (c) 0.017 0.241 0.083 -0.416 0.007 0.235 
0.209 (p) 0.948 0.336 0.742 0.086 0.980 0.347 
medial 
tumor 
tissue 
[ng/mg] 
-0.121 (c) 0.137 0.207 0.186 -0.176 0.105 0.211 
0.633 (p) 0.587 0.409 0.460 0.486 0.680 0.401 
Whole 
tumor 
[ng/mg] 
-0.286 (c) 0.069 0.269 0.140 -0.351 0.047 0.262 
0.250 (p) 0.787 0.280 0.578 0.153 0.852 0.293 
Table 7: Correlation (c) between temperature [°C] and DOX concentration [ng/mg] with 
their corresponding p-values (p) 
3.3.4 PHARMACOKINETICS 
Plasma DOX concentration for all groups at 2 min after injection was 32.0 ± 10.0 ng/mg 
and decreased significantly (p < 0.01) to 7.7 ± 5.2 ng/mg after 60 min. 
The lowest DOX concentration after 60 min was found 1.9 ± 1.0 ng/mg for the water bath 
with the large tumor. The highest DOX concentration of HT was found for the laser exper-
iments in small tumors with 12.5 ± 2.6 ng/mg (Figure 15).  
 
Figure 15: DOX concentration in plasma for all time points in ng/mg: pre-injection (blank), 
2 min (hatched) and 60 min (dotted) 
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To compensate for the differences in the manner of injection, the 60 min values were 
normalized on 2 min plasma concentration value. The water bath heating groups demon-
strated the highest decrease in DOX concentration compared to the other heating meth-
ods. The concentration dropped to 8.3 % ± 0.1 % and 12.4 % ± 10.5 % for animals with 
large and small tumors, respectively. For the lamp experiments, there were residual con-
centrations of 38.7 % and 24.7 %. For the laser experiment, 29.0 % and 39.6 % was meas-
ured for large and small tumors, respectively. 
  
Figure 16: Normalized DOX concentration in plasma after 60 min of treatment. 
The differences in normalized DOX concentration were significant between the lamp and 
the water bath (p = 0.05) and between the laser and water bath experiments (p = 0.02). In 
contrast, the difference between the laser and lamp heating method was not significant 
(p = 0.84).  
In terms of the different tumor sizes, there were no significant differences (p > 0.05) be-
tween the groups due to the small group sizes. However, there was a tendency for higher 
plasma DOX concentration within the small tumors (Fig. 17) 
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Figure 17: Plasma DOX concentration for all time points grouped by the different tumor siz-
es and heating methods: 2 min (blank) and 60 min (hatched) 
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3.4 DISCUSSION 
Temperature in the tumor is used as an external trigger for drug release and thus for drug 
targeting in regional mild HT-induced doxorubicin release using TSL. There are many 
studies investigating the drug uptake, heat distribution, and therapy outcome with differ-
ent heating and carrier systems. Laser light for HT itself has been examined for mild HT by 
different studies [79,94–96]. In combination with encapsulated cisplatin Dou et al. used 
laser light induced mild HT to heat up a murine subcutaneous tumor and investigated the 
drug enhancement in the whole tumor and temperature distribution in the heated tumor 
[82], which is discussed more detailed in the following section.   
Laser light is a challenging heating source and—depending on the tissue, perfusion, and 
wavelength—different heating patterns can be achieved. Laser light used for laser surgery 
is commonly used in cancer therapy (15172 hits on PubMed) as well as LITT (1290 hits on 
PubMed), where deterministic effects are used for therapy. On the other hand, searching 
for ‘mild HT and laser’ generates 58 hits on PubMed and it is thus not as common in cancer 
therapy. Although temperature is a key factor, there seems to be no study comparing effec-
tiveness of different HT methods for inducing drug release in vivo. Therefore, the different 
studies where drug carrier systems are examined regarding their potential for cancer 
therapy are difficult to compare. 
Therefore, three different heating methods for mild HT were compared which were either 
newly developed or have been often used in small animal models before. To facilitate 
comparability, the tumor model, the DOX-TSL, the experimental timeline, and minimum 
tumor temperature were the same for all experiments. To assess the effectiveness of heat-
ing and drug release in the tumor, different key factors, including temperature distribu-
tion, tumor size, drug enhancement, and pharmacokinetics were examined.  
The cold light lamp and water bath were selected for comparison with the new method as 
both were already established in our group [20,74] and thus allowed optimized therapies 
and improved assessment of the effectiveness. Requirements that led to the development 
of a new device were non-invasiveness, MRI-compatibility, and tumor selective heating in 
small animals. Other methods such as external FUS or RF heating systems—although al-
ready in clinical use—were not considered here for several reasons. The TSL release 
mechanism in FUS was considered not fully comparable because a mechanical trigger is 
added to the temperature trigger. RF was not considered because of its technical complex-
ity, especially in the MRI environment.  
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3.4.1 HEATING 
For laser and lamp heating, the temperature gradients were comparable and no significant 
difference was recorded. The unexpected effect of a smaller temperature gradient in the 
lamp experiment with large tumors, compared to the other methods, can be attributed to 
the use of two-armed gooseneck lamps, which were positioned on two opposite sides of 
the tumor. With this setup, it is assumed that it should be possible to heat up larger tumors 
more homogenously compared to smaller tumors, where the two lamps are naturally clos-
er, and the tumor is effectively heated from above. The laser light causes a higher tempera-
ture gradient for heating up large tumors when compared to the other devices, and thus 
may not be as well-suited if homogeneous temperature distribution throughout a larger 
volume (above 2.5 cm3) is of interest. This inhomogeneity might be reduced by an optical 
system where the light (wavelength = 763 nm) emanates from different directions, as used 
by Dou et al. in 2014 [82]. They used their system in combination with liposomal cisplatin 
in mice with a tumor size of max 0.4 cm³ (maximum 6 – 9 mm tumor growth in one di-
mension). Further studies are required to investigate the possible implications of such a 
system for larger tumors (up to 2.5 cm3), such as those investigated in this work. 
By heating the whole leg, using warm water, a lower temperature gradient was achieved 
for the water bath experiment. The blood was pre-warmed and the tumor was heated 
from all sides.  
To assess the likely unintended negative impacts of HT, like necrosis, skin burn, or oede-
mas, CEM43°C in the tumor was calculated. In addition, acute effects on heated tissue were 
evaluated visually. According to publications by Dewhirst et al., Rhoon et al., and Yar-
malenko et al., acute minor tissue damage can be expected from 40 - 80 CEM43°C [97–99], 
and acute and chronic tissue damage can be expected above 81 CEM43°C. Thus, a higher 
CEM43°C in the superficial probes results in a higher probability for “degree one” (red skin, 
epidermis involved, no blisters, dry textures) to “degree two” burns. Red skin was seen in 
one laser experiment with a large tumor, one with a small tumor, and for two experiments 
heated with the lamp with a small tumor. These symptoms were found in animals with 
calculated single probe equivalent minutes above 40 CEM43°C. However, a precise defini-
tion of the degree of burning was not possible due to the immediate removal of the tumor, 
which precluded long term observations to assess such damages.  
In 1992, Waldow et al. presented a study where superficial RIF-1 tumors (1.0 cm³) in mice 
were superficially heated with a 1064 nm laser [100]. Waldow achieved a temperature 
gradient of 1.5 °C/mm in the tumors. Its temperature gradient was calculated from the 
given temperature probe depth and the mean temperature difference in the probes. The 
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measurements indicated a temperature of up to 52 °C and above on the surface of the tu-
mor for a target temperature of 42.5 °C. Tissue necropsy, blanching, or necrotic areas were 
observed up to 5 mm depth 48 h after HT. These side effects were not expected to occur 
from the heating methods used in this thesis because the temperature gradient achieved 
by Waldow et al. was three times higher than that achieved in these experiments. The gra-
dient difference may be explained as either an effect of differences of vascularization and 
the resulting blood flow of the different tumor models (no data available), or the modula-
tion of the laser power. Our preliminary experiments with CW heating demonstrated a 
high temperature gradient compared to the later used modulated laser power. Thus, the 
high temperature gradient achieved with the 1064 nm laser by Waldow might be attribut-
ed to the CW-Laser. The different wavelengths should only have a minor effect because 
both are in the NIR window, which provides a high penetration depth of the light.  
3.4.2 DOX ENHANCEMENT 
To exclude unwanted DOX release induced by the heating mattress, three muscle samples 
were taken from the abdominal wall after the experiment and analyzed with HPLC. The 
analysis  indicated a smaller DOX concentration (0.5 ± 0.1 ng/mg; 2 mg/kg TSL-DOX) 
compared to previous experiments (> 2.5 ng/mg; 5 mg/kg TSL-DOX) [86]. Even if the DOX 
concentration in the muscle tissue is normalized on the injected dose, it is recorded at half 
of the drug concentration compared to previous experiments [86]. Any noteworthy DOX 
release caused by the heating mattress can be excluded. The impressive stability of the 
liposomes used for temperatures beneath Tm is likely responsible for the integrity of the 
results in that respect.  
When comparing heated and unheated tumors, a significantly improved DOX enhance-
ment was seen. Here the DOX concentration was 16 – 17 fold higher in the heated com-
pared to the unheated tumors using the lamp, and 13 – 15 fold higher using the laser heat-
ing. Compared to HIFU studies summarized by Hijnen et al. (DOX 2-5 mg/kg BW [24] re-
view) or other HT methods [101], the DOX concentration achieved here is of the same or-
der of magnitude. In the HIFU studies, different injection protocols, HT protocols and heat-
ing methods were used, which resulted in an increase of between 2.7 and 22.4 fold [24], 
which may be explained by the huge variation within the experimental setups. These data 
demonstrate the usability of the laser heating device and illustrate the effectiveness of 
DPPG2-TSL.  
As the volume of a rat leg is approximately 3% of the rat’s body weight (own observation) 
or 9 g for a 300 g rat respectively, DOX tissue concentration in the tumor decreased by a 
different order of magnitude than the heating volume increased. Such a proportion indi-
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cates that most of the drug is still released in the heated tumor and not in the heated leg, 
but the difference in DOX concentration in the tumor compared to light and laser heating 
is still significant (p = 0.02) for whole tumors. The effect might be a result of higher per-
meability of the vessels, the higher perfusion in tumor tissue generally, additionally in-
creased by HT, which is discussed further on. Nevertheless tumor-specific heating should 
be achieved to avoid possible side effects such as skin irritation due to DOX accumulation 
in surrounding tissue [86]. 
3.4.3 INTERDEPENDENCE BETWEEN HEATING AND DOX ENHANCEMENT 
DOX enhancement was highly significant for all three heating methods. The results con-
firm interdependence between temperature distribution, applied heating method, and 
tumor size. The achieved DOX-concentration in the small tumors was higher across all 
experiments when compared to the DOX concentration in larger tumors. One potential 
explanation for the concentration disparity is that the injected dose of DOX was the same 
for both groups, while the heated tumor volume where DOX was released was different. 
This is supported by a significant negative correlation between tumor size and the overall 
DOX-concentration in the tumor. This effect is slightly less evident in the water bath exper-
iment, which is described further on. The absolute DOX concentration for the water bath 
was the lowest, which might be caused by the larger heated tissue volume compared to the 
laser or lamp experiment. The larger heated tissue volume was larger because the heated 
volume included the whole leg with the. 
Contrary to the expected effect that there is an increase in drug tissue concentration with 
higher tumor temperatures, there was no significant effect on the DOX concentration. A 
possible reason for that is that, if a specific temperature (> 40 °C) is reached, the drug re-
lease out of the liposomes will not be further enhanced [18,102]. Otherwise, it is known 
that the blood flow in tumorous tissue increases at temperatures above body temperature 
at HT temperature. Therefore, a higher blood flow in warmer regions—for example in 
lateral parts of the tumors—should deliver  better drug availability, and thus a higher drug 
concentration. This effect is reversed when the temperature increases above 43 °C – 44 °C 
[103,104], which can have a negative effect on the perfusion. Nevertheless, a tendency of 
temperature dependency and DOX in tumor tissue was observed, and thus a temperature 
above Tm and an as homogeneous as possible heating pattern is crucial for therapy with 
TSL. Consequently, the most homogenous DOX concentration and temperature distribu-
tion was achieved with the water bath experiment; heating the whole leg increases the 
total tissue volume where DOX is released, while the total amount of DOX-TSL remains the 
same. Thus, the absolute amount of DOX delivered to the tumor volume decreases relative-
ly. 
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3.5 CONCLUSION 
An adequate heating of subcutaneously applied rodent tumors was possible with all three 
investigated heating methods. Both, laser and lamp heating achieved local HT treatment of 
only the tumor tissue. The heating pattern and the heat-triggered DOX release from 
DPPG2-TSL into the heated tumor tissue were comparable for both methods. The ad-
vantages of the lamp system are an easy steering of the light source, significant lower costs 
and no need of laser associated personal and protective equipment like safety google and 
facilities with restricted access. If an MRI-compatible heating device is necessary, a laser-
based HT system is preferably used as an easy MRI-appropriate guidance of laser power to 
the heated tissue. To provide a sufficient heating pattern, a maximum of 2.5cm³ tumor 
volume should not be exceeded.  
In contrast, a water bath yields a more homogenous heating pattern, but since the whole 
leg is heated, the HT treatment is regional rather than local. Therefore, the achieved DOX 
enhancement ratio is significantly lower than those observed in the other two heating 
methods. This renders the occurrence of unwanted side effects in the normal tissue of the 
heated leg more likely, which highlights the exigency of therapy studies. 
This standardized comparative study demonstrated that the tumor size and the method of 
heating must be considered when comparing the efficacy of temperature-induced drug 
release in subcutaneous experimental tumors. Drug delivery and drug targeting through 
the use of DPPG2-TSL was shown to be even more efficient when using tumor specific 
heating. The heterogeneous DOX tissue concentration demonstrated the necessity for vis-
ualization of drug release and drug concentration in tumor tissue to improve the outcome 
of chemotherapy that uses DPPG2-TSL. 
The new laser light applicator is a valuable tool for exploration of local mild HT in subcu-
taneous tumor models. Consequently, the applicator was chosen for further investigation 
of drug-loaded TSL combined with mild HT and MR-Imaging. 
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4. THERAPY MONITORING WITH MRI 
For locally advanced cancer, chemotherapy is commonly used within multimodal treat-
ment strategies. In order to improve antitumor efficacy, knowledge of local tissue drug 
concentration would contribute clear advantages. At this point, drug concentration can 
only be derived from invasive biopsies. The limitation of biopsies is that only a small part 
of the tumor can be analyzed, neglecting the possibility of heterogeneous perfusion, vary-
ing vessel permeability, various interstitial fluid pressures, or different types of tissues 
(like necrosis) throughout a single tumor. These distinct tissue characteristics also result 
in a heterogeneous drug distribution within the tumor volume and then tissue characteris-
tics complicate optimal therapy planning. Therefore, non-invasive imaging methods that 
survey the whole tumor, like MRI [29], PET [28], SPECT [105], are under development for 
drug dose painting or chemodosimetry.  
Therapy monitoring of chemotherapy with TSL and imaging could facilitate more person-
alized medicine that achieves a better therapy response. Furthermore, as described in 
chapter 3, the temperature distribution in the treated volume influences drug release. 
Thus, the aim of this part of the work was to investigate an imaging method for non-
invasive 3D temperature measurement and to structure a method for estimation of drug 
delivery into tumor tissue.  
For image-guided drug delivery with TSL, MRI offers unique features. Encapsulation of 
paramagnetic MRI CA, such as the clinically utilized Gd-DTPA, allow the assessment of 
additional information on drug release and temperature pattern during therapy [29,63]. 
This is based on the indirect effect of CA on MRI signals in comparison to other imaging 
methods, such as X-ray, as described previously (Chapter 2.5.9). 
The first step of this study involves verifying that a sufficient release of MR contrast agent 
with the laser light applicator is possible. Secondly, the possibility of MR-thermometry in 
the presence of CA-TSL is investigated in combination with drug dose painting, which is 
the subject of controversial discussions [106–109].  
The third and final step of the study consists of testing a variety of static and dynamic MR 
parameters as surrogate markers for the quantification of HT-induced DOX release in tu-
mors, using a mixture of TSL loaded with CA or DOX. 
Parts of this section (Chapter 4.) are published in the Journal Of Controlled Release by 
Peller and Willerding et al. 2016 [110]. 
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4.1 MATERIALS AND METHODS 
4.1.1 EXPERIMENTAL SETUP 
Six rats with two tumors each—one in each hind leg—were treated with DOX-TSL com-
bined with CA-TSL during a dynamic MRI-measurement. 
The rats were prepared (chapter 4.1.2) for the experiment eleven days (+ 2 days) before 
MR-Imaging and HT. For the MRI, the rat was positioned in the MRI-receiver coil (SMS 
Precision Eight Wrist Array Coil, Invivo, USA) together with the laser HT applicator. After 
T1-, T2, and PD weighted measurements for morphologic information and T1 quantification 
of the tissue, a dynamic scan was started. After baseline measurement, mild HT was in-
duced with the laser applicator in four of the six rats, while two animals remained unheat-
ed as a control group. Once the temperature in the probe had reached a stable value above 
40 °C, CA-TSL (0.1 mmol/kg) was injected simultaneously with DOX-TSL (2 mg/kg) (Sup-
plementary table 4, 5 and 6) (duration of bolus: ~ 10s). The tumor temperature was 
thereafter kept constantly above 40°C (preparation of liposomes is described in chapter 
3.2.1). 60 min after injection, the laser was switched off, but the dynamic scan continued 
for another 20 min during cooling of the tumor. 
After the MRI scan, the heated tumors were excised and prepared for HPLC analysis. Two 
tissue probes per rat (one sample of heated tumor and one not-heated tumor sample) 
were analyzed by HPLC. Static and dynamic MRI-information were used for further analy-
sis. Post-processing was executed within the software “PMI”, which was (0.4) developed 
in-house.  
For further examination of therapy monitoring, the following parameters were evaluated: 
the AUC of T1-relaxation time over time, difference of T1 relaxation time before and after 
heating, and the phase difference. Furthermore, dynamic and static phase change was con-
sidered. 
4.1.2 ANIMAL MODEL 
Experiments were performed in accordance with approved protocols (Regierung von 
Oberbayern, AZ. 55.2.-1-54-2532-144-11). The experiments were performed under anes-
thesia (isofluran 2-5 % and oxygen 1.5 l/min), administered with an isofluran evaporator.  
Animal preparation with tumor for a bulk tumor: For tumor growth, 1.5x106 / 50 µl BN175 
cells were injected in one hind leg. Tumor growth was recorded with caliper measure-
ments. The volume was calculated using an ellipsoid approximation (equation 19). After 
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10-14 days, the volume reached 1 cm3 and the tumor was removed as a bulk tumor. Frag-
ments of about 2x2x2 mm3 of this tumor were stored in liquid nitrogen.  
Animal preparation with tumor for MRI investigation: Fragments from the bulk tumor were 
implanted into a new animal. The advantages of this method compared to injection of cells 
are more homogenous tumor growth, prevention of cell dispersion, and prevention of in-
vasive tumor growth.  
For implantation of tumor pieces, both hind legs of the rat were shorn, and the skin was 
opened with a surgical scissor. The tumor was then implanted as deeply as possible in a 
subcutaneous tube. The wound was closed with a suture. Tumor growth was measured in 
three planes every second day, and the volume was calculated as described in the preced-
ing study. 
The exact size of the tumor at the time of the MRI experiment could not be fully measured 
because of restricted availability of measurement time on the clinical MRI-scanner. The 
tumors were allowed to grow for at least 11 days. Depending on the availability of scan 
time, there was a variation of + 2 days. 
During MRI, body temperature was controlled by a rectal temperature probe and a water 
heating mattress. To prevent liposomes from releasing the drug due to the heating mat-
tress, the water temperature was kept below 39 °C. To reduce MRI flow artifacts caused by 
the heating mattress, 20 mMol/L MnCl2 was added to eliminate the signal from the water 
of the heating mattress by strong decreasing T2*. 
4.1.3 INVASIVE TEMPERATURE MEASUREMENTS 
As a reference for MR thermometry, and to monitor absolute tumor temperature, invasive 
temperature measurement was performed using one intratumoral fiberoptic temperature 
probe (ReflexTM Signal Conditioner, Neoptic Inc., Canada) for tumor temperature control, 
and one rectal probe for body temperature measurements. The tumor probe was implant-
ed with the assistance of a cannula (20G needle, BD MicrolanceTM, Germany). The principle 
of probe implantation is described in figure 18. Morphologic MR-images were used to con-
trol the position of the temperature probe after bringing the rat into the MR-Scanner. 
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Figure 18: a) – b) insertion of the cannula including the needle in the lower third of the tu-
mor c) needle was removed, cannula stayed inside the tumor d) – e) insertion of the temper-
ature probe f) cannula was removed 
After insertion, the probe was fixed to the rat with tape. The rectal tumor probe was in-
serted approximately two centimeters and fixed with tape to the rat’s tail. 
Tumor and body temperature were measured every second during the MRI experiments, 
and data was recorded every 10 seconds (via an AD converter with a laptop). 
4.1.4 MRI TEMPERATURE MEASUREMENT 
The sensitivity of T1 to temperature change is tissue-dependent. This dependency factor m 
was determined for each animal. Therefore, dynamic T1 change (ΔT1) from a region of in-
terest (ROI) around the tumor probe tip was fitted with the corresponding temperature 
change (ΔTprobe) from the tumor probe in equation 22. 
∆𝑇𝑝𝑟𝑜𝑏𝑒 = 𝑚 ∗ ∆𝑇1 
22 
To exclude the influence of injected TSL with CA, only data before injection of CA-TSL was 
used.  
The PRFS coefficient was set to -0.01 
𝑝𝑝𝑚
°𝐶⁄  because it is mainly independent of tissue 
characteristics, as described by Rieke et al. [63] (see chapter 2.5.8). 
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4.1.5 HEATING 
Tumors were heated with the laser light as described in chapter 3. To verify a minimum 
temperature of 40 °C throughout the whole tumor during the experiment, the required 
target temperature in the tumor probe was estimated with the tumor probe depth and the 
temperature gradient demonstrated in chapter 3.3.2. The target temperature was calcu-
lated with equation 23. 
𝑇𝑡 = 𝑑𝑇 ∗ ∆𝑝𝑑 + 𝑇𝑚𝑖𝑛, 
23 
where Tt is the target temperature, dT/dx as temperature gradient that is set to 
0.48 °C/mm (Table 3), Tmin is the minimum target temperature of 40°C and Δpd is the dis-
tance from the base of the tumor to the tumor probe. Tumor probe depth was measured in 
the pd-, T1- or T2- weighted morphological images on the MRI workstation. 
4.1.6 MR ACQUISITION 
Measurements were performed on clinical 3-T whole-body system (MAGNETOM Verio & 
MAGNETOM Skyra, Siemens Healthcare, Germany). For signal acquisition, a dedicated 
8 channel wrist coil (SMS Precision Eight Wrist Array Coil, Invivo, USA) was used. Applied 
sequences and MR parameters are described in later sections. 
Morphological Imaging 
Prior to the T1-quantification and MRI temperature measurements, T1 weighted (TR/TE, 
15.3/6.4 ms, 4 averages, FA = 10°) and a T2 weighted (TR/TE, 6240/95 ms, 3 averages, 
FA = 142°), turbo spin echo images of 22 sagittal slices with a slice thickness of 2.5 mm 
were acquired using a 62 x 90 mm2 FOV and a matrix size of 264x384. The total acquisi-
tion time for morphological images was around 15 min. These images were used for tumor 
localization and size measurements. 
T1 Quantification 
As described above, T1 can be used for temperature mapping and it is—for a defined 
range—a linear indicator of contrast agent concentration. In the following section, the 
sequences for T1-quantification and dynamic measurement are described. 
For static and dynamic T1 mapping the variable FA method was used.  
TWIST sequence 
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For T1 mapping a 3D-gradient echo sequence with view-sharing was also used. In conven-
tional MRI-sequences, the whole k-space is sampled for one image at a time, whereas the 
TWIST (Time-resolved Angiography With Stochastic Trajectories) sequence (Siemens 
Healthcare, Germany) shares parts of k-space for several images and achieves accelerated 
data acquisition for one image with the so-called “data sharing-method”. As the inner k-
space is responsible for the image contrast, the TWIST sequence samples only the inner k-
space for every time point, while the outer k-space is only sampled partially, and missing 
parts are filled using previously acquired k-space data [111].  
A 3-D-k-space is sampled with a readout direction in kx and a phase-encoding direction in 
ky and kz. As described by Laub et al. in 2006 [112], all points are sorted by their polar 
coordinates. The first sorting criterion is the distance kr from the middle of the phase-
encoding plane with: 
𝑘𝑟 = √𝑘𝑦
2 + 𝑘𝑧
2 
24 
The sampling points were subdivided according to their radial distance kr from the center 
of the k-space in two groups: Group A with kr<KC representing the points with low spatial 
frequency and Group B with kr>KC the points with high spatial frequency. Group B was 
randomly divided into different subgroups Bj with j = 1, 2, 3,…, N. During a dynamic image 
acquisition, the k-space is sampled only once in total. This happens either at the beginning 
or at the end of the dynamic acquisition. For the other time points, only area A and one 
subgroup Bj is sampled. To obtain complete k-space information, the next time point is 
sampled with area A and subgroup Bj+1 until the whole k-space is sampled. Missing data 
for a specific time point are taken from previous (backward data sharing) or following 
(forward data sharing) acquisitions (Figure 19).  
 
Figure 19: Reconstruction of k-space: continuous lines show “forward data sharing” and 
dashed lines show backward data sharing. Differing brightness show the different Bj. 
The time required to obtain a reconstructed image (nominal time resolution TATWIST) can 
be described with: 
Timeline 
Data parts acquired 
at a certain time 
point 
Added data sets 
needed to calculate 
image 
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𝑇𝐴𝑇𝑊𝐼𝑆𝑇 = 𝑇𝐴𝑓𝑢𝑙𝑙(𝑆𝐴 + (1 − 𝑆𝐴)𝑝𝐵) 
25 
Where TAfull is the acquisition time for the whole k-space, SA is the normalized size of sam-
pling area A and pB is the sampling density of area B. Hence, two parameters influence the 
total acquisition time: with a reduction of the area A or by lowering the sampling density 
of area B, the required acquisition time can be reduced. 
B1 inhomogeneities and flip angle correction 
For accurate and precise T1-mapping with the VFA method, a homogenous RF transmis-
sion field (B1) is needed. The inhomogeneities of the RF pulses necessitate correction of 
the FA, particularly at high magnetic field strengths. In 2006, Cunningham et al. suggested 
a technique to quantify the FA error [113] using a modified double angle method (DAM) 
for correction. DAM was previously described by Stollberger et al. [114] and Insko et al. 
[115]. Such a method allows the calculation of a flip angle map, which is an indirect meas-
urement of the B1 field.  
Two images are acquired: I1 with a flip angle α1 and another image I2 with α2 = 2α1. If all 
other signal-affecting sequence parameters are kept constant, the ratio of the magnitude 
images is [113]: 
𝐼2(𝑟)
𝐼1(𝑟)
=
sin𝛼2(𝑟) 𝑓2(𝑇1, 𝑇𝑅)
sin𝛼1(𝑟)  𝑓1(𝑇1, 𝑇𝑅)
 
26 
where r represents the spatial position of every voxel and α1(r) and α2(r) are the attendant 
local flip angles. For long repetition time (TR ≥ 5 T1), f1 and f2 = 1. Cunningham’s DAM was 
modified for the TWIST sequence used here because radial readout was not possible, and 
the reset sequence employed to bring the spin population to the same state regardless of 
their excitation, was not available. A long repetition time was used during which the longi-
tudinal magnetization was recovered, and thus the actual flip angles can be written as: 
𝛼(𝑟) = 𝑎𝑟𝑐𝑐𝑜𝑠 (|
𝐼2(𝑟)
2𝐼1(𝑟)
|) 
27 
For the flip angle correction, a TWIST sequence—as described in a later section—was also 
used. For I1; α1 was set to 22° and for I2; α2 was 11°. The TWIST sequence was limited to a 
maximum FA of 23° before changing the RF pulse type. The highest possible FA was cho-
sen for stability reasons as a higher FA facilitates a more robust FA correction [116]. Aside 
from the dynamic measurements, K-space was sampled in total for every image. To mini-
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mize T1-effects, TR was set to 5000 ms. In order to reduce the acquisition time, parallel 
imaging (SENSE; R = 2) was used and matrix size was halved in the in-plane direction 
while maintaining the FOV—as used in the TWIST sequence—and using interpolation to 
fill in the missing data points. Total acquisition time for flip angle correction was 10 min 
and α(r) was calculated retrospectively. Relative FA (αrel) map for correction was calculated 
with: 
𝛼𝑟𝑒𝑙 =
𝛼(𝑟)
𝛼𝑝𝑟𝑒𝑠𝑒𝑡⁄  
28 
where αpreset is the FA as set in the sequence parameter and α(r) is the calculated real FA 
from equation 27. 
Static and dynamic T1-mapping with the VFA method 
Static T1 -mapping 
For relaxation time mapping before and after cooling (baseline mapping), a T1 -
measurement was used with seven different flip angles (5°, 7°, 10°, 12°, 15°, 18°, 23°) 
within the following parameters.   
TWIST parameters were SA = 30, pB = 20. The matrix size was 132 x 192 x 22 with FOV of 
62 x 90 x44 mm³ and the receiver bandwidth was 200 Hz/pixel. TR was fixed to 10.12 ms 
and TE to 6 ms. The relative long TE was chosen for PRFS measurement during dynamic 
measurement. TR was minimized as far as possible. Five averages were acquired for each 
flip angle to increase the SNR for baseline measurement. Total acquisition time was 
8.5 min for a complete T1-map. Baseline T1 and M0 map was calculated pixel-by-pixel by 
linear fitting of the FLASH equation to the acquired data for the linearized data of VFA 
measurements. 
Dynamic T1-mapping 
For fast T1 quantification during the treatment, a single FA mapping method was used. To 
reduce systematic errors, sequence parameters were optimized . 
As described by Dietrich et al. in 2014 [62], a statistical error in dynamic T1-mapping with 
one FA can be estimated by equation 29 (see also figure 20): 
∆𝐸1,𝑑𝑦𝑛 ≈
(1 − 𝐸1,𝑑𝑦𝑛 ∗ cos(𝛼𝑑𝑦𝑛)) ²
S0 sin(𝛼𝑑𝑦𝑛) ∗ (1 − cos(𝛼𝑑𝑦𝑛))
∆Sdyn 
29 
Therapy Monitoring with MRI 58 
 
where 𝐸1,𝑑𝑦𝑛 = exp (−𝑇𝑅/𝑇1,𝑑𝑦𝑛). This error is a function of αdyn, defining a unique mini-
mum for the optimal flip angle αdyn,opt for dynamic T1 measurements. The optimal FA αdyn,opt 
can be calculated by: 
𝛼𝑑𝑦𝑛,𝑜𝑝𝑡 = arccos
2𝐸1 − 1
2 − 𝐸1
 
30 
where 𝐸1 = exp (−𝑇𝑅/𝑇1). For the TR = 10.12 ms, as used in this case, the optimal FA for 
different T1 relaxation times is shown in figure 20. 
 
Figure 20: a) The minimum error as a function of T1 for given TR is indicated by the dotted 
red line. For comparison, the Ernst angle is shown as a solid green line. Statistical error 
ΔE1,dyn of dynamic T1 measurement as a function of T1 and FA is shown grey-scaled. b) Statis-
tical ΔE1,dyn error for 15°, 23°, and 30° (red, green and blue) is dependent on T1. Statistical 
error for the optimal FA for every T1 is marked with a black dotted line. The estimated T1 
interval is marked with two vertical black lines [62]. 
Estimated T1 times in the rat tissue before, during, and after the treatment were 
400 ms - 1600 ms. Therefore, for the dynamic T1 measurement with one FA, 23° was cho-
sen because it provides a low and stable estimated error across the whole T1 range (Fig-
ure 20 b)). All other parameters except the averages stayed the same as the static baseline 
T1-measurement described before. Time resolution for one time point was set to 9.73s.  
Equation 31 was used to calculate dynamic longitudinal relaxation time T1,dyn for each pix-
el and for every time point t, considering the actual flip angle from preceding DAM meas-
urement. 
𝑇(𝑡)1,𝑑𝑦𝑛 = −𝑇𝑅 𝑙𝑜𝑔⁄ (
𝑀0 ∗ sin𝛼 − 𝑆(𝑡)𝑑𝑦𝑛
(𝑀0 ∗ sin𝛼) − 𝑆(𝑡)𝑑𝑦𝑛 ∗ cos𝛼
) 
31 
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Where TR is the repetition time, M0 is the baseline proton density map acquired by the 
multi-FA measurement, α is the used flip angle, and S(t)dyn is the dynamic signal at time 
point t. 
PRFS measurement 
Phase information was also reconstructed from the dynamic TWIST sequence raw data. 
Thus, a dynamic phase data set with the same sequence parameters as the magnitude im-
ages and T1 calculation was reconstructed retrospectively. For post-processing, phase dis-
continuities caused by > 2 π phase jumps were corrected by adding an integral number of 
cycles. One-dimensional phase unwrapping that detects jumps of more than a half cycle in 
the data set was applied using the MATLAB unwrap function [117]. As only the phase 
change in the time dimension was evaluated, in-plane phase unwrapping was not neces-
sary. The algorithm was implemented in PMI software. These phase data were used for 
temperature determination before injection based on equation 18 and as a surrogate 
marker for chemodosimetry, as described thereafter. For correction of phase drift caused 
by magnetic field drift and coil sensitivity during long experimental time periods, the 
phase information of unheated tight muscle was used.  
4.1.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS V22 (IBM, Germany). The correlation analy-
sis employed the concept of bivariate correlation according to Pearson. Differences be-
tween two data sets were established using the parametric two-tailed student’s t-test. 
Normal distribution was tested with the Kolmogorov-Smirnov-test. For regression analy-
sis, fit models were tested with the ANOVA test [93]. p-values were considered to be “sig-
nificant” if they were less than or equal to 0.05, and “highly significant” when less than or 
equal to 0.01. Modified Bland Altman plots, as described by Krouwer [118], were calculat-
ed by MATLAB R2012a (MathWorks Inc., Natick, USA). 
4.2 DRUG QUANTIFICATION WITH MRI / CHEMODOSIMETRY 
To quantify drug delivery in tumor tissue, several semi-quantitative and quantitative pa-
rameters derived from the dynamic and static T1-time information and the phase infor-
mation were considered as potential parameters to predict the invasive DOX measure-
ment. Semi-quantitative derived parameters based on signal intensity from the signal 
curve depend strongly on acquisition parameters and external influences, such as coil sen-
sitivity. Therefore, only quantifiable parameters, such as dynamic and static T1-values and 
the dynamic phase change information, were used for drug concentration measurements. 
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In particular, the correlation between the HPLC DOX-concentration and MRI-parameters 
was examined. 
The following parameters were determined from either T1 or the phase-dynamic tissue 
curve, as illustrated in figure 21. 
 AUC for relative and absolute T1 change during the treatment (T1_1FA_AUC_rel 
[%*s]; T1_1FA_AUC_abs [ms*s]) 
 Relative and absolute T1 difference for total acquisition time measured with one 
FA (T1_1FA_total_rel [%]; T1_1FA_total_abs [ms]) 
 Relative and absolute T1 difference for the therapy time measured with one FA 
(T1_1FA_treatment_rel [%];T1_1FA_treatment_abs [ms]) 
 AUC for proton resonance frequency shift [rad*s] during the treatment 
(Phase_AUC [rad*s]) 
 Absolute proton resonance frequency shift during the treatment (Phase_diff [rad]) 
Furthermore, the VFA measurement with 7FA was used for the analysis of: 
 Relative and absolute T1 time difference for total acquisition time measured with 
seven FA (T1_7FA_rel [%]; T1_7FA_abs [ms]). 
 
 
Figure 21: Illustration of several descriptive parameters that were utilized: AUC (grey); total 
T1 difference; treatment T1 difference. The red line depicts the dynamic temperature data. 
ROI were chosen manually from the dissected tumor volumes, slice by slice, until the total 
tumor volume was considered (Figure 22 c). ROIs of a tumor were summarized to a vol-
ume of interest (VOI). For each VOI, mean values for each MR parameter were calculated. 
The ANOVA test was used in order to establish whether a linear regression was a suitable 
surrogate parameter for DOX, and HPLC DOX-concentration was used as the independent 
variable. These mean MRI parameters were correlated with the DOX concentration deter-
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mined by HPLC using a linear regression analysis of the data from all of the animals 
(Figure 22 d). Parameter maps were then calculated pixel-by-pixel with this DOX concen-
tration (Figure 22 e). For further analysis, the VOIs of each heated tumor were halved to 
represent the two halves obtained by bisecting the tumor during excision (Figure 22 c). 
For all VOIs, mean DOX values were calculated from MRI DOX maps and compared to cor-
responding DOX measured by HPLC. These data were fed into a Bland Altman plot where 
the reproducibility coefficient (RPC = 1.96*SD of mean error) facilitated comparison of the 
different MRI markers (Figure 22 f).  
The procedure for calculating tissue DOX concentration based on static T1-measurement is 
illustrated in figure 22 for the relative T1 time difference before and after HT 
(T1_1FA_treatment_rel). The figure uses the procedure of DOX calculation representative-
ly, as an example for other parameters. 
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Figure 22: Procedure for calculating T1-based liposomal DOX concentration from 
T1_1FA_treatment_rel as an example for other parameters. a) Corresponding T1-map [ms; 
0 ms – 2000 ms] before injection calculated with 1 FA b) Corresponding T1-map [ms; 
0 ms - 2000 ms] before cooling down calculated with 1 FA c) Calculated T1-time difference 
[%/100] with used ROI’s (H1  lateral tumor part; H2  medial tumor part; NH  unheated 
reference tumor) for correlation drug concentration in tissue d) Results for HPLC validated 
DOX measurements [ng/mg] from each animal compared to corresponding T1-difference for 
whole tumors with resultant linear regression e) Pixel-by-pixel calculated DOX concentra-
tion map [0 ng/mg – 20 ng/mg] f) Bland Altman plot for HPLC validated DOX measurements 
[ng/mg] for all animals and whole tumors (black, solid, dot) and halved tumors (red, dashed, 
triangle) compared to MRI calculated DOX concentration [ng/mg].  
a) b) 
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4.3 RESULTS 
All six animals were examined successfully: the four animals in which one tumor was ex-
posed to mild HT (rat weight of 313 g ± 75 g; N61, N62; N84; N85) were included in group 
A, and two without HT (357 g ± 33 g; N66, N67) were included in group B as a control 
group. HPLC analysis was performed on the 18 tumor samples. Tumor volume was 1.2 cm3 
with a standard deviation of 0.7 cm3 for heated tumors and 1.0 cm3 ±1.3 cm3 for unheated 
tumors. Two animals exhibited a reddish skin with no signs of burning on the heated tu-
mor. In the proton density weighted images, all tumors demonstrated a relatively homo-
geneous hyperintense signal compared to muscle tissue with few hypointense structures. 
The T1 weighted images depicted hypointense structures uniformly distributed through-
out the whole tumors, with a tendency towards an appearance in the medial part of tumor. 
In the T2 weighted images, the tumors were hyperintense with hypointense structures. No 
specific CA enhancement patterns, such as those described by Ponce et al., were detected 
[101]. 
The target temperature calculated with equation 23 and the measured tumor tempera-
tures for all experiments are displayed in table 8. For animal N85, T1 mapping with 7 FA 
after treatment was not possible due to motion artefacts. For one experiment (N62), a 
temporal malfunction of the laser resulted in temperature fluctuation throughout the 
therapy, but a mean temperature of 40.2 ± 0.7 °C was still achieved. Two animals re-
mained unheated as reference. All animals were used for analysis. 
Animal 
distance to 
base [mm] 
Target tem-
perature [°C] 
mean tumor tem-
perature with SD [°C] 
N61 1 40.4 40.3 ± 0.1 
N62 2 40.9 40.2 ± 0.7 
N84 1 40.4 40.2 ± 0.1 
N85 4 41.9 41.9 ± 0.1 
N66 1 unheated 32.9 ± 0.1 
N67 2 unheated 33.7 ± 0.3 
Table 8: Distance to the base of the tumor with corresponding target temperature and 
reached mean tumor probe temperature during therapy with SD for all MRI experiments. 
The laser heating device induced no visible artefact at with the distance of 10 mm between 
the metal coating of the prism and the tumor. Laser light did not interfere with the tem-
perature probe.  
All shown MRI pictures are from animal N62 and serve as representative examples of the 
rest of the experiments. 
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4.3.1 T1-MEASUREMENT AND VALIDATION 
Flip angles for T1 calculation were corrected by a relative flip angle map (Figure 23 b)) 
measured for each animal. For every tumor-VOI and region in the muscle, the mean T1 was 
calculated (Table 9) from corresponding T1-maps (Figure 23 c)-f)). 
 
    T1 time (ms) 
  
VFA (7FA) VFA (1FA) 
Animal / 
Group 
tumor part prae post prae post 
N61 / A 
h
ea
te
d
 t
u
m
o
r 
1586 657 1446 459 
N62 / A 1498 1030 1539 998 
N84 / A 1363 983 1300 879 
N85 / A 1557 X 1369 890 
Mean 1501 (99) 890 (203) 1414 (103) 807 (238) 
N61 / B 
re
fe
re
n
ce
 t
u
m
o
r 
1617 1458 1544 1111 
N62 / B 1846 1338 1909 1344 
N66 / B 1467 935 1480 1029 
N67 / B 1386 805 1430 968 
N66 / B 1807 1150 1827 1315 
N67 / B 1472 1013 1581 1279 
N84 / B 1557 1145 1505 1044 
N85 / B 1559 X 1331 1200 
Mean 1589 (163) 1121 (227) 1576 (197) 1161 (143) 
N61 
m
u
sc
le
 
1302 1353 1307 1325 
N62 1372 1323 1243 1074 
N66 1350 1215 1339 1234 
N67 1411 1254 1329 1285 
N84 1349 1289 1167 1116 
N85 1406 X 1394 1223 
Mean 1365 (41) 1287 (55) 1279 (80) 1210 (97) 
Table 9: T1 [ms] values before and after therapy for the heated tumor (A), reference tumor  
(B) and muscle tissue for all experiments as well as the different T1 measurement methods 
pre-heating and post heating. ROIs for muscle has 150 pixels in one plane. SD values are giv-
en in brackets. 
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Figure 23: a) Representative morphologic proton density image. b) Corresponding relative 
FA map gained by the DAM-method. c) - f) T1-relaxation times acquired with the VFA Method 
with seven FA and with one FA before and after the treatment. 
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4.3.2 PHASE SHIFT MEASUREMENT 
Phase shifts acquired by the dynamic TWIST sequence were used for temperature meas-
urements and drug dose painting, as described previously. Phase shift ranged from -
1.19 rad to +0.12 rad for whole tumors after injection of CA-TSL. Injection of CA-TSL had 
only minor effects on phase change in the muscle tissue that lasted less than 2 min. 
4.3.3 TEMPERATURE MEASUREMENT 
Temperature data from the fiberoptic temperature probe 
A target mean temperature level of 40°C was reached for all animals treated with mild HT. 
Body temperature did not reach a temperature above 37 °C. For every experiment except 
for N62, temperature was kept constant above the target temperature. During the N62 
experiment, a technical malfunction of the laser led to short periods (~ 4 x 120 s) with no 
heating. During these periods, temperature decreased below the target temperature. 
Temperature data for all experiments is shown in table 10.  
 
    After injection 
Experiment  
number 
T10 
(°C) 
T50 
(°C) 
T90 
(°C) 
Mean tumor 
temperature (°C) 
Maximum tem-
perature (°C) 
G
ro
u
p
  
A
 
N61 40.4 40.3 40.1 40.3 ± 0.1 40.6 
N62 40.6 40.4 37.7 40.2 ± 0.7 41.4 
N84 40.3 40.2 40.1 40.2 ± 0.1 40.4 
N85 42.0 41.9 41.1 41.9 ± 0.1 42.2 
       
G
ro
u
p
 
B
 N66 32.7 32.7 32.5 32.9 ± 0.1 33.0 
N67 33.8 33.6 33.4 33.7 ± 0.3 34.8 
Table 10: Temperature data from the temperature probe after injection of drugs until 1 h 
after injection. T10 and T90 denote 10% or 90% of the temperature data were above this 
temperature level. 
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MRI temperature measurement 
Temperature maps based on MRI were calculated retrospectively using PRFS and with T1 
change as described in chapter 2.5.8 and 4.1.4. Results are shown in figure 24. For T1 tem-
perature measurements, the temperature dependency was determined to be 1.2 %/ °C, as 
described in chapter 4.1.4. Accuracy of the temperature measurements was within + 0.4 °C 
with a standard deviation of ± 1.1 °C for experiments with HT and 0.7 °C ± 1.5 °C for all 
experiments in the same ROIs as in PRFS temperature measurement (Table 11). After in-
jection of CA-TSL, an error of up to ± 30 °C occurred in T1 and PRFS temperature meas-
urements.  
 
  PRFS T1 
Experiment mean error [°C] SD [°C] mean error [°C] SD[°C] 
N61 0.1 0.8 -0.2 1.2 
N62 -0.1 0.9 0.1 1.5 
N66 -0.2 1.1 0.3 1.9 
N67 1.3 3.1 2.2 2.6 
N84 0.0 1.0 0.9 0.6 
N85 0.0 1.2 0.6 1.1 
Mean 0.2 1.4 0.7 1.5 
Table 11: Mean error for temperature measurement from start of measurement until injec-
tion of TSL and temperature in the tumor right before injection with SD as an indicator for 
temperature distribution for all experiments. 
Temperature change calculated with PRFS indicated a significant (p < 0.000) correlation of 
about 0.944 to temperature change measured with the fiberoptic probe before injection of 
the CA-TSL for all experiments. This is demonstrated by a temperature change measure-
ment with an accuracy of -0.1 °C and with a standard deviation of ± 1.0 °C for experiments 
with HT and 0.2 °C ± 1.35 for all experiments within a ROI (amount of pixel 6 < n <15) 
around the tip of the probe from the beginning of heating until injection. By contrast, after 
injection MRI temperature measurements revealed an error from -2 °C up to + 9 °C for all 
experiments. 
Temperature histograms and temperature standard deviation from the heated tumor just 
prior to injection were developed as an indicator for temperature distribution in the heat-
ed tumor. Figure 24 illustrates the temperature histogram corresponding to temperature 
maps for animal N62. Temperature maps generated with PRFS resulted in a homogeneous 
temperature map, while T1-generated maps showed a higher noise level. 
Dynamic tumor temperature data for N62 is shown in figure 25 (a) visualize the tempera-
ture curve before and after injection during laser malfunction. Immediate strong fluctua-
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tions were observed for temperature changes around 40 °C for the T1 based parameter. 
The temperature curve for an experiment with a temperature above the target tempera-
ture for the entire duration of the treatment is shown in figure 25 (b). There were no rapid 
changes during the treatment in the T1 and PRFS temperature measurements. The calcu-
lated temperature after injection of CA-TSL yields unrealistic temperature values, and data 
was only shown in figure 25 to demonstrate this effect. 
  
Figure 24: Temperature map axial cross-section of rat with heated and reference tumor for 
a) PRFS and b) T1 based temperature change calculation for each pixel immediately before 
injection c) - d) corresponding temperature histogram to analyze temperature distribution 
in the heated tumor on the left side. 
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Figure 25: a) Dynamic temperature curves for experiment N62. Temperature changes meas-
ured by probe were caused by temporal malfunction of the laser. b) Dynamic temperature 
curves for experiment N84. Vertical solid black lines shows the injection and the end of heat-
ing while the dashed black lines mark temperature changes from above to below 40 °C. 
4.3.4 HPLC DOX CONCENTRATION 
HPLC analysis was used as reference for drug dose painting and was performed success-
fully in the 18 tumor samples. The mean DOX concentration of heated tumors in group A 
was 10.6 ± 2.6 ng/mg, and 1.2 ±0.4 ng/mg for unheated tumors in group A. Tumors in the 
control group B resulted in a DOX value of 2.1 ± 1.1 ng/mg. Comparing HT-induced drug 
delivery, the mean DOX ratio for heated to unheated tumors in Group A was 9.4 ± 2.9 (5.3 
– 13.1). For group B, the mean ratio was 1.3 (1.1 and 1.6). DOX concentrations by HPLC of 
the two halves in the bisected tumors were juxtaposed and were seen as indicators of in-
tratumoral homogeneity of DOX release. The mean ratio between the lateral and the medi-
al DOX concentration was 1.9 ± 1.1 for the heated tumors in group A and 1.1 (1.0 and 1.3) 
for the unheated tumors of group B. This indicates a higher DOX concentration in tumor 
tissue, which is closer to the results obtained using the laser applicator.  
4.3.5 CHEMODOSIMETRY 
The overall aim of the study was to facilitate accurate prediction of drug concentration in 
tissue with MR-imaging. Static measured T1 values (Table 9), phase difference, and param-
eters containing dynamic information were generated from dynamic tissue curves (Fig-
ure 26) and static measurements.  
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Figure 26: Representative dynamic tissue curves for T1, PRFS and signal enhancement for 
the heated tumor. From these tissue curves, MR parameters were extracted for further in-
vestigation. 
Correlation coefficients between HPLC DOX concentration and MRI parameters were ana-
lyzed and are shown in table 12. The AUC of the dynamic phase (Phase_AUC) and the rela-
tive T1 change showed the highest correlation with the HPLC DOX-concentration, whereas 
the relative T1 time difference (T1_7FA_rel) resulted in the lowest correlation. Correspond-
ing correlation of the medial, lateral and unheated tumor to HPLC DOX concentration is 
shown in supplementary table 7, where the r-values are of the same order of magnitude as 
the data in table 12. 
With these data, linear regressions (y = m * x +a) were calculated and used for drug dose 
painting, and the calculated DOX concentrations were analyzed by a modified Bland Alt-
man Plot (Fig. 22 f) afterwards. 
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linear regression of MRI Parameter and HPLC DOX concentration 
regression with HPLC DOX-concentration and Slope (m) 
Intercept (a) 
[ng/mg] 
R p 
st
at
ic
 d
at
a 
T1_1FA_total_abs [(ng/mg)/ms] -27.1 -352.7 -0.648 < 0.0005 
T1_1FA_total_rel [(ng/mg)/%] -2.2 -21.4 -0.764 0.004 
T1_1FA_treatment_abs [(ng/mg)/ms] -42.5 -341.3 -0.819 0.001 
T1_1FA_treatment_rel [(ng/mg)/%] -2.7 -21.6 -0.857 0.023 
T1_7FA_abs [(ng/mg)/ms] -19.9 -417.2 -0.496 0.287 
T1_7FA_rel [(ng/mg)/%] -1.5 -26.0 -0.335 0.145 
Phase_diff [(ng/mg)/rad] -0.070 0.039 -0.847 0.001 
d
y
n
am
ic
 
d
at
a 
Phase_AUC [(ng/mg)/(rad*s)] -97.4 -329.0 -0.856 < 0.0005 
T1_1FA_AUC_rel [(ng/mg)/(%*s)] 9.6*10-3 -61.6*10-3 -0.842 0.001 
T1_1FA_AUC_abs [(ng/mg)/(ms*s)] -1.5*10-5 -8.8*10-5 -0.793 0.002 
Table 12: Data for linear regressions of HPLC DOX with different MRI parameters with their 
corresponding r-values as correlation factor and their p-values (0.000  p<0.0005). DOX 
concentrations and ROI values of whole tumors were used for correlation. 
With this information and the measured HPLC DOX-concentration, MRI DOX-
concentration maps were calculated pixel-by-pixel with equation (32): 
𝑫𝑴𝑹𝑰 = 𝒎 ∗ 𝑷𝑴𝑹𝑰 + 𝒂 
32 
were DMRI is the DOX concentration in ng/mg calculated with the corresponding MRI Pa-
rameter PMRI, slope (m) and intercept (a) from table 12. 
As a control, the calculated DOX concentrations were compared to the HPLC-DOX concen-
tration for each region, and then fitted with a linear model (Figure 28, table 13). . The AUC 
of the relative dynamic T1 time change has a slope nearest to one, and the lowest intercept 
difference from zero, while the relative T1 time difference has the highest slope and the 
highest intercept difference from zero. Linear regression and corresponding Bland Altman 
plots are shown in figure 28 for HPLC and MRI DOX-concentration. The smallest reproduc-
ibility coefficient (RPC = 1.96*SD of mean error) was found for the AUC of the dynamic 
phase and for the relative T1 difference before and after treatment, measured with 1 FA 
with 5.6 ng/mg. The highest RPC was found for the relative and absolute T1 difference 
measured before and after heating with 7 FA, recorded at 13.7 ng/mg and 17.0 ng/mg, 
respectively.  
As an internal control, the results of bisected tumors were analyzed as well (supplement 
table. 10). The calculated DOX concentrations corresponding to the bisected tumors were 
comparable to those of the whole tumors (supplement table 11). Additionally, DOX con-
centration of unheated muscle was calculated and compared to the muscle DOX concentra-
tion gained by experiments from chapter 3 (figure 27). Data used, are shown in supple-
mentary table 8 and 9. 
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Linear regression of MRI calculated DOX and HPLC DOX concentration 
regression with HPLC DOX and MRI DOX of 
Slope Intercept r² 
RPC 
(ng/mg) 
static 
data 
T1_1FA_treatment_rel  0.69 1.46 0.818 5.6 
T1_1FA_treatment_abs 0.66 1.27 0.765 6.5 
T1_1FA_total_rel 0.70 0.51 0.658 7.8 
T1_1FA_total_abs 0.53 1.16 0.550 10.9 
T1_7FA_rel 0.46 1.53 0.405 13.7 
T1_7FA_abs 0.37 1.92 0.377 17.0 
Phase_diff 0.69 1.01 0.760 5.8 
dynamic 
data 
Phase_AUC 0.72 1.09 0.813 5.6 
T1_1FA_AUC_rel 0.69 1.16 0.772 5.9 
T1_1FA_AUC_abs 0.58 1.16 0.721 7.1 
Table 13: Linear regression for measured vs. calculated DOX values for every ROI in 
[(ng/mg)/(ng/mg)]. Data were generated with data from table 12. The RPC factor was gen-
erated from the Bland Altman plot. 
 
 
 
Figure 27: Mean DOX concentration with standard deviation determined by MRI parameters 
in group A and B compared to DOX concentration determined by HPLC. DOX concentration in 
muscle was determined in preceding experiments (chapter 3).  
Therapy Monitoring with MRI 73 
 
 
Figure 28-1: Left: Scatterplots for whole tumors HPLC tissue DOX concentration [ng/mg] 
compared to the extracted MRI parameter with linear regression. Middle: Representative 
image with pixelwise calculated DOX concentration [ng/mg] for N62. Right: Bland Altman 
plot for HPLC DOX concentration [ng/mg] compared to the MRI DOX-concentration [ng/mg] 
for whole tumors (black, solid line, dots) and lateral and medial tumor parts. (red, dashed, 
triangle).  
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Figure 28-2: As described in figure 28-1. 
  
Therapy Monitoring with MRI 75 
 
4.4 DISCUSSION 
Thermosensitive liposomes supply an advancement towards temperature-induced target-
ed chemotherapy. The encapsulated drug is protected against metabolism and interaction 
in the human body, and can reach the target tissue easily. Several types of chemotherapeu-
tics, such as doxorubicin, gemcitabine and miltefosine [20,119] as well as different MR 
contrast agents [88], can currently be loaded into the liposomes. This method contributes 
to targeted chemotherapeutic therapy, while CA-release from the liposomes with MR-
imaging can also be characterized by different MRI parameters.  
In this work, various MR parameters are analyzed to determine their potential use for 
drug dose painting. For this purpose, static and dynamic tissue parameters were com-
pared to their corresponding drug concentration. To develop a system for clinical use, it is 
necessary to minimize patient stress, so well-tolerated and clinical approved components 
must be used in injections. In this study, FDA-approved gadolinium-based MRI-CA and 
FDA-approved chemotherapeutical drug doxorubicin were encapsulated in TSL. The ad-
ministered DOX-dosage (2 mg/kg) was selected according to the usual dose for cancer 
treatment in humans [34]. The applied dosage of CA is a well-tolerated dose used for clini-
cal MR-imaging [120]. All lipids used in this study were declared safe in the Anatomical 
Therapeutic Chemical classification system ATC  
4.4.1 DRUG RELEASE 
Drug delivery after injection of mixed DOX- and CA-TSL during laser-induced mild HT was 
highly effective, as evidenced by the enhanced DOX release in the heated tumors. This re-
sult was in accordance with the findings in chapter 3 using the same DOX-TSL and experi-
mental setup, but with the addition of three temperature probes in the tumor. As the heat-
ing method and DOX-TSL were the same, these previous data were assumed directly com-
parable, thus the HPLC DOX concentration in muscle was used to compare with MRI-
determined DOX concentration in muscle tissue.  
4.4.2 HEATING OF THE TUMOR 
As shown in chapter 3.3.2, the laser heating device provides a relatively homogeneous 
heat pattern with no signs of long term side effects in the subcutaneous tumor HT. In con-
trast to the experimental setup used for validation of the laser light applicator, only one 
temperature probe was used. The tumor probe was implanted in the medial third of the 
tumor, which guaranteed measurement of the temperature in the tumor volume at the 
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minimum temperature level or above (see chapter 3). To reach a minimum temperature of 
40 °C in the whole tumor, target temperature was chosen depending on probe position.  
Mean tumor probe temperatures differed from the target temperature by less than or 
equal to - 0.2 °C, which provides a sufficient heating expectation of less than half a millime-
ter. This was considered to be an adequate heating. For one experiment (N62), a laser mal-
function caused a variation in temperature (40.2 ± 0.7 °C), which resulted in a temporary 
tumor temperature less than 40 °C. This was accepted because chemotherapy should also 
work on tumors that are not adequately heated. 
Temperature determined with one tumor probe for the whole heating volume is question-
able if inhomogeneities in the temperature distribution are present. Therefore, MRI tem-
perature measurements by T1, or with PRFS, were performed to examine tumor tempera-
ture in the whole tumor.  
MRI thermometry is capable of mapping temperature change. The results demonstrated 
that there was a temperature decrease from the tumor part near the laser light applicator 
to the opposite side.  
4.4.3 MRI MEASUREMENTS 
T1 quantification 
Since, a rapid CA release from the TSL was assumed to be a key mechanism, a fast gradient 
echo image sequence was applied.  
The T1 time difference between the VFA method with one and with seven flip angles is less 
than 36 ms ± 180 ms (SD). Furthermore, measured T1-time for muscle tissue at body tem-
perature (1377 ms ± 79 ms (SD)) corroborates human muscle tissue data in the literature 
(1412 ms ± 13 ms (SD))  [121]. 
For T1 calculation, a source of a systematic error was neglected in order to realize a quick 
acquisition time. For the dynamic VFA-method, it was assumed that T2* and M0 remain 
constant over the whole treatment time to permit the use of only one flip angle during the 
dynamic scan, which accelerated the acquisition rate. To establish whether this assump-
tion is justified, a measurement was performed after the treatment with the entire set of 
all flip angles as acquired before injection. The T1 value obtained in this manner was com-
pared to the T1-time calculated from the last acquired time point with one flip angle and 
the M0 from the previous measurement. This resulted in an error of -36 ms ± 144 ms (SD) 
in T1 quantification. Therefore, in agreement with Dietrich et al. [122]—where a relevant 
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error in T1 measurement only occurs for higher CA concentrations—the T2* effect and 
changes of M0 can be neglected. 
A limitation of the flip angle correction used in this work is that it does not apply to the 
whole dataset, for example, wherever the signal was bad due to decreased receiver coil 
sensitivity for the outer regions of the FOV and wherever there was a resulting bad signal 
to noise ratio. This phenomenon had no effect for evaluation because the tumor slices 
were located in the center of the FOV. 
Temperature measurement 
For an accurate and precise temperature measurement with the T1 relaxation time, a tis-
sue-dependent factor is necessary. This factor was calculated for the tumor tissue with the 
data from all of the animals. Temperature change measurements by MRI before injection 
were possible with an accuracy of ± 0.7 °C ± 1.5 °C. After injection, MRI temperature 
measurement based on T1 depicted a significant deviation from the temperature detected 
by the fiber-optic probe. This was expected for the T1-temperature measurement because 
of the CA-induced T1 change. Therefore, a temperature change measurement with the T1 
relaxation time in combination with liposomes-encapsulated CA-is not possible. On the 
other hand, when exceeding the phase transition temperature, the T1 time changes rapidly. 
This data could be used for absolute temperature measurements and is observable in ex-
periment N62 (Figure 25), in which exceeding or falling below the Tm leads to a significant 
change in the longitudinal relaxation time. This effect changes the MRI-signal when ex-
ceeding the phase transition temperature and was illustrated in vivo by Peller [74]. This 
works as long as CA-TSL are present and CA is not completely released. The limitation of 
this method is that only one temperature level can be measured. 
Phase measurements are always affected by phase drift during long lasting, repeated 
measurements. This phase drift was corrected with a reference in less perfused muscle 
tissue, where a low CA enhancement is expected, promising the lowest error for drift cor-
rection after injection. Fat tissue is more suitable for drift correction because of its low 
perfusion and absence of hydrogen bonding that results in insensitivity to temperature 
change [123]; however, there was insufficient available adipose tissue for drift correction. 
Due to the restricted volume in the receiver coil, no external phantom for drift correction 
could be used. However, the high accuracy (-0.21 °C) of PRFS temperature measure-
ments—before injection—shows that the drift correction aided by a reference tissue was 
sufficient.  
Changes in T1 and T2 time should have no effect [124] on temperature measurement with 
the PRFS method, but the results reveal a mismatch relative to the invasive temperature 
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measurement after injection. This effect was also described by Hijnen in 2013 [107]. This 
discrepancy cannot be explained by relaxation time change, because normally the PRFS 
method is based on change in the shielding constant of the H-nucleus and a change in re-
laxation time should have no effect on the phase shift [125]. The deviation in temperature 
measurements assumed to be caused by a susceptibility change. The temperature sensitiv-
ity of the susceptibility can be neglected for temperature measurement normally [63], but 
the susceptibility change caused by CA-TSL and free CA is much higher. These CA-induced 
susceptibility fluctuations influence the local magnetic field around the nucleus, resulting 
in a change of Larmor frequency, and thus in an error with the PRFS temperature. There-
fore, an accurate temperature measurement for mild HT with T1 time change or with the 
PRFS method is was not possible after injection of CA-TSL. 
4.4.4 CHEMODOSIMETRY 
The main objective of this study was to estimate drug concentration in target tissues using 
MRI parameters. Until now, the parameter of choice for drug dose painting with TSL and 
mild HT was T1. The preceding studies compared T1 maps acquired before and after HT for 
chemodosimetry [101,126]. In this study, T1- and PRFS-based data were used, which were 
acquired before and after (static data) as well as during the treatment (dynamic data). One 
challenge for this work was the accurate placement of the ROIs corresponding to the ex-
cised tumor parts for the heated tumor and are a potential source of error 
For drug dose painting, the CA concentration was not calculated. On one hand there is the 
linear correlation between relative T1 change and CA concentration in a defined range of 
CA concentration, and on the other hand there is a tissue- and temperature-dependent 
relaxivity of gadolinium-based CA [127]. Thus, a precise calculation of CA-concentration 
was not possible because data, such as the r1 for every temperature and the tumor tissue, 
were not available.  
It is assumed that a linear correlation between relative T1 change and CA concentration— 
a nonlinear correlation for absolute T1 change—may explain why static and dynamic 
change for absolute T1 parameters has a lower correlation coefficient to the HPLC DOX 
concentration compared to the relative T1 change parameters.  
Additionally, the PRFS measurement was used for drug dose painting. The hypothesis was 
that this parameter facilitates a better prediction of the drug concentration in the tumor 
compared to T1-quantification because of TSL’s characteristics. This means that water 
exchanges through the membrane as the temperature rises. Above Tm, the drug is released. 
As mentioned before, the water exchange induces a T1-change without drug release. Fur-
thermore, the PRFS method was used by Korporaal et al. in 2011 to quantify contrast 
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agent concentration and to obtain the concentration of CA in an arterial input function for 
perfusion measurement [128]. Korporaal determined that the phase change is linear to the 
amount of MR-CA, even for high concentrations.  
Temperature change after reaching the target temperature was neglected in this paper 
because the temperature in the tumor was relatively stable. A temperature change of 
± 1 °C over the whole treatment time (60min) would generate a calculated error of 
± 0.9 
ng
mg⁄  for DOX quantification, which is minimal, compared to the RPC, and therefore 
was assumed acceptable. 
The calculated drug concentration in the present work evidences a better correlation for 
dynamic MRI acquisition (AUC of T1-change or Phase-change) compared to the static data, 
whereas the AUC for relative T1 change is slightly better than the PRFS method. On the 
other hand, the PRFS method does not require additional B1 correction measurements, 
which reduces total scan time. This would be beneficial in clinical use. To simultaneously 
measure T1 and phase change, sequence parameters were adapted to provide sufficient 
quantification for both parameters. Drug dose painting could be improved by selecting a 
specific MRI marker with optimized sequence parameters that are modified especially for 
T1 time measurements (shorter TE, longer TR) or for phase measurement (longer TE). For 
phase measurements, a longer TE generates a larger phase change when all other se-
quence parameters are held constant. This larger phase change supplies a higher SNR and 
thus better drug dose painting and temperature sensitivity, whereas for T1-time meas-
urement, a shorter TE, and a longer TR lead to a higher SNR, and thus to a better drug dose 
painting and temperature sensitivity as well. 
In the literature, the possibility of in vivo monitoring for drug release is calculated qualita-
tively, but only a few studies have performed quantitative drug dose painting 
[28,30,31,101]. In 2007, Viglianti et al. and Ponce et al. demonstrated that drug dose paint-
ing was feasible with MRI. They used a MnSO4-doxorubicin TSL in combination with mild 
HT [26,29,101]. In these studies, an implanted water tube passing through the tumor in-
duced HT. Tissue probes were taken, analyzed by HPLC, and correlated to the CA uptake 
after the treatment. Viglianti et al. revealed a linear regression between the CA-uptake 
calculated DOX concentration in the tumor and the tissue DOX-concentration of 
0.86 ± 0.48 (SD) (
𝑛𝑔 𝑚𝑔⁄
𝑛𝑔 𝑚𝑔⁄
), and an intercept of -0.01 ± 10.05 (SD) (ng/mg) in 2006 [29]. 
They used only the CA enhancement calculated from two T1-maps, one acquired before 
and one acquired after heating. Ponce recorded a T1 map every 90 s in order to calculate 
drug concentration for the whole tumor. The MRI DOX concentration at the last time point 
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was compared to an HPLC measurement, which demonstrated no significant difference. 
There was no further statistical analysis reported from Ponce et al.. 
It is assumed that a drug dose painting based on T1 acquired at only two time points be-
fore and after HT neglects processes that occur during the treatment, such as washout of 
CA from the tissue, while drugs like DOX exhibit rapid intercalation with DNA and are 
permanently built into the cell. This might be compensated for by Mn2+, which binds to 
DOX and prompts a DOX-CA relationship. This binding reduces the error of a washout of 
the MRI-CA, and thus can be beneficial for drug dose painting when CA and DOX are com-
bined in one TSL. But there is also an interaction of Mn2+ with the head groups of the lipo-
somes that reduce the drug retention capability of the TSL [129]. Furthermore, Mn2+ is 
toxic and thus cannot be used in patients. 
For further studies, it has to be considered if the high temporal resolution used in this 
work is necessary. For example, a higher SNR could be achieved with longer acquisition 
time and a high temporal resolution as it is needed for perfusion is not necessary due to 
the fact that no arterial input function needs to be acquired. 
For a clinical application, it has to be investigated if drug dose painting with these imaging 
methods is possible. Thus, it is not possible to inject the CA- and DOX-TSL as a bolus be-
cause of the high injection volume, which makes an infusion necessary. It also has to be 
investigated if this type of chemodosimetry is possible for different chemotherapeutics.  
4.4.5 LIMITATIONS 
Dynamic T1 mapping with one FA is affected by neglecting the T2* effect of CA. This error 
increases with increasing CA concentration and with decreasing FA as described by Die-
trich et al. [122]. Therefore, without T2* correction the calculated T1 values were systemat-
ically too high. The estimated maximum error of 3 % for the setup used in this work can 
interfere with the drug dose painting.  
During a long lasting MR-measurement, a phase drift can occur, which has to be compen-
sated for. In this work an internal muscle reference was used instead of an external refer-
ence due to a lack of space. To exclude a possible error using internal references because 
of contrast agent or movement, external reference phantoms may be an advantage for 
PRFS measurements.  
MR temperature measurements with CA-TSL depend on the setting of the pulse sequences 
and are discussed in the literature. Fossheim et al. [73] reports susceptibility effects while 
investigating in vitro TSL encapsulating Gd-DTPA-BMA. Apart from the type of CA, such 
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susceptibility depends on the size of the liposomes and the susceptibility difference be-
tween the vesicle interior and exterior [130]. This suggests that MR thermometry based 
on the chemical shift of the proton resonance frequency, which is determined by phase 
changes, is sensitive to CA-TSL injection and heat induced release of CA from TSL. Hijnen 
et al [131] considered this as potentially relevant to MR thermometry for HIFU guidance in 
combination with co-encapsulated gadolinium-based CA, although such effects were not 
reported in earlier studies [109]. The same group verified an effect in phantom and in vivo 
muscle tissue [107]. Therefore, temperature measurements using phase shift must be veri-
fied in the presence of CA-TSL for every experimental setting. 
Absolute temperature measurements are especially necessary for subcutaneous tumors 
because of the difference between body and tumor temperature and—as noted in chap-
ter 3.3—a possible temperature gradient before heating.  
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5. CONCLUSION 
Drug delivery through the combination of DPPG2-TSL encapsulating DOX and the new la-
ser applicator in a clinical MRI setting was highly effective when a minimum temperature 
of 40°C was achieved in the targeted tumor; these conditions resulted in an almost 10-fold 
higher DOX tissue concentration compared to the unheated tumor.  
For visualization, a new approach was tested using a mixture of DPPG2-TSL encapsulating 
either DOX or CA showing that this is a promising method for following HT-triggered local 
DOX delivery with MRI. This approach has several advantages over the application of TSL 
with co-encapsulated drug and CA. Firstly, complexity in development of single compound 
formulations is significantly reduced. Secondly, independent dosing of drug and CA is facil-
itated in vivo, whereas co-encapsulation allows application with only a fixed dose-ratio. 
Finally, other formulations containing gemcitabine [11], such as DPPG2-TSL, could be easi-
ly investigated in MRI by adding CA-TSL. 
Besides determining T1 parameter maps at specific time points, as preferred in literature, 
other MRI parameters were also identified as promising surrogate marker for DOX accu-
mulation in tumor tissue. Phase-based MR thermometry was severely affected by the 
presence of CA-TSL; however, for the first time, this CA-TSL-related phase change was 
demonstrated to be suitable for the assessment of DOX concentration. Tumor temperature 
was stable during HT, and MRI surrogate markers acquired during HT were preferable 
over the previously preferred change in T1 possible using TSL with co-encapsulated drug 
and CA. 
MRI-derived parameter maps of DOX concentration demonstrated local differences, indi-
cating that visualization of CA released from TSL could be usable for targeting HT to a spe-
cific tissue volume. This concept must be investigated in more detail in future studies.  
In conclusion, promising MRI surrogate parameters were also identified for the assess-
ment of DOX tissue concentration when using a mixture of CA-TSL and DOX-TSL. 
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6. SUPPLEMENT 
6.1 CHEMICALS 
The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) were obtained from Corden Pharma 
Switzerland LLC (Liestal, Switzerland). 1,2-distearoyl-sn-glycero-3-phosphodiglycerol 
(DPPG2) was synthesized as described above [40]. DOX was purchased from Sigma Aldrich 
GmbH (Munich, Germany) and Gd-DTPA-BMA (OmniscanTM) was from GE Healthcare 
Buchler GmbH & Co. KG (Braunschweig, Germany). The FCS came from Biochrom AG (Ber-
lin, Germany). All other chemicals were either from Carl Roth GmbH (Karlsruhe, Germany) 
or from Sigma Aldrich GmbH (Munich, Germany). Purified, deionized water generated 
with the Milli-Q Advantage A10 system (Merck Millipore, Billerica, MA, USA) was used in 
all experiments. 
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6.2 COMPARISON AND VALIDATION OF HEATING METHODS 
6.2.1 CHARACTERIZATION OF LIPOSOMES 
Lipid 
(mM) 
DOX 
(mM) 
DOX/Lipid 
(mol/mol) 
z average 
(nm) 
PDI Zeta poten-
tial (mV) 
DPPG2 
(%) 
Lyso-PC 
(%) 
21.6 
(± 4.6) 
3.0 
(± 0.6) 
0.14 
(± 0.02) 
104 
(± 10) 
0.11 
(± 0.06) 
-24.7 
(± 3.7) 
30.5 
(± 6.1) 
0.1 
(± 0.2) 
Supplementary table 1: Characterization of DPPC/DSPC/DPPG2 50/20/30 (mol/mol) TSL 
(DPPG2-TSL) formulations encapsulating DOX. Four independent preparations have been 
used. The molar content of DPPG2 and Lyso-PC was quantified with thin layer chromatog-
raphy. The standard deviation is given in parentheses. PDI: polydispersity index. 
 
Temperature (°C) kDOX (10-4 s-1)  
 HN buffer FCS 
37 0.2 (0.787) 0.9 (0.895) 
38 0.3 (0.975) 3.2 (0.917) 
39 0,7 (0.987) 10.0 (0.992) 
40 3.3 (0.973) 51.8 (0.998) 
41 30.5 (0.953) 73.0 (0.895) 
42 53.0 (0.990) 105.7 (0.954) 
Supplementary table 2: Release kinetics of DOX from DPPC/DSPC/DPPG2 50/20/30 
(mol/mol) TSL (DPPG2-TSL) measured with fluorescence spectroscopy, as described previ-
ously [18]. Calculated DOX release rate constants kDOX from measurements performed in (A) 
20 mM HEPES, 150 mM NaCl (HN buffer), pH 7.4 (n = 3), and (B) FCS (n = 3). The coefficient of 
determination (R2) is given in parentheses. 
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6.2.2 SUPPLEMENTARY DATA 
 
Supplementary figure 1: Transmission curve for color filter “RED” (kindly provided by Op-
tich PL 2000, Photonic Optische Geräte GmbH & Co. KG, Austria) 
 
Experiment DOX concentration [ng/mg] 
   
lateral tumor 
part 
medial tumor 
part 
whole 
tumor 
reference 
tumor 
L
am
p
 la
rg
e N20 18.9 7.0 14.2 0.8 
N23 23.4 2.0 13.5 1.0 
V33 28.0 14.6 18.7 1.3 
sm
al
l V23 23.2 23.4 23.3 2.0 
V36 24.6 21.6 22.6 1.2 
V37 24.8 20.9 23.4 1.0 
L
as
er
 la
rg
e N44 9.7 5.1 7.0 0.9 
V27 2.8 7.9 6.1 0.6 
V39 22.1 14.5 18 1.0 
sm
al
l N47 31.6 14.2 23.3 0.9 
V21 22.3 13.3 19.7 1.1 
V29 19.4 10.9 14.8 1.8 
W
at
er
 b
at
h
 
la
rg
e V26 3.6 5.7 4.5 0.7 
V32 5.4 4.6 4.8 1.6 
V35 3.2 5.2 4.3 1.0 
sm
al
l V24 5.3 7.2 6.1 1.6 
V28 9.2 9.3 9.3 1.7 
V38 20.9 27.0 24.5 1.0 
Supplementary table 3: HPLC DOX-concentration for all experiments and tumor parts. DOX 
concentration for the whole tumor was subjected to a weighted calculation by weight of tu-
mor parts.  
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6.2.3 TECHNICAL DRAWINGS 
  
Supplementary figure 2: Lensholder 
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Supplementary figure 3: Lensholder disc 1 
Supplement 88 
 
 
  
Supplementary figure 4: Lensholder disc 2 
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Supplementary figure 5: Outer tube 
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Supplementary figure 6: Inner tube 
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6.3 THERAPY MONITORING WITH MRI 
6.3.1 CHARACTERIZATION OF LIPOSOMES 
 Lipid 
(mM) 
DOX 
CA 
(mM) 
DOX/Lipid 
CA/Lipid 
(mol/mol) 
z average 
(nm) PDI 
Zeta 
potential 
(mV) 
DPPG2 
(%) 
Lyso-PC 
(%) 
DOX-TSL 
30.9 
± 6.9 
3.8 
± 0.1 
0.13 
± 0.03 
118 
± 4 
0.09 
± 0.01 
-27.9 
± 1.8 
25.7 
± 10.1 
0.6 
± 1.0 
CA-TSL 
29.5 
± 2.7 
12.9 
± 2.7 
0.44 
± 0.12 
128 
± 24 
0.12 
± 0.08 
-20.6 
± 1.9 
24.9 
± 6.0 
0.0 
± 0.0 
Supplementary table 4: Characterization of DPPC/DSPC/DPPG2 50:20:30 (mol/mol) TSL 
(DPPG2-TSL) formulations with encapsulated DOX and Gd-DTPA-BMA. Three independent 
preparations have been used. The molar content of DPPG2 and Lyso-PC was quantified with 
thin layer chromatography. Mean values are displayed with standard deviations. PDI: poly-
dispersity index. 
Temperature (°C) kDOX (10-4 s-1) 
37 0.9 (0.895) 
38 3.2 (0.917) 
39 10.0 (0.992) 
40 51.8 (0.998) 
41 73.0 (0.895) 
42 105.7 (0.954) 
Supplementary table 5: Release kinetics of doxorubicin (DOX) from DPPC/DSPC/DPPG2 
50:20:30 (mol/mol) TSL (DPPG2-TSL) measured with fluorescence spectroscopy, as de-
scribed previously [18]. Calculated DOX release rate constants kDOX from measurements 
performed in FCS (n = 3). The coefficient of determination (R2) is given in parentheses. 
Temperature 
(°C) 
r1  
(s-1 mM-1) 
SD 
(s-1 mM-1) 
30.0 0.93 0.22 
31.9 0.94 0.14 
33.8 1.11 0.11 
35.7 1.23 0.12 
37.6 1.37 0.07 
39.6 1.84 0.14 
41.5 4.00 1.27 
43.4 4.17 0.96 
45.3 4.02 0.75 
47.2 4.11 0.76 
49.2 4.28 0.94 
Supplementary table 6: Mean r1 relaxivity of CA-TSL (DPPC/DSPC/DPPG2) 50:20:30 
(mol/mol) TSL (DPPG2-TSL) measured by a 0.47 T NMR-analyzer (Minispec NMS120, Bruker 
BioSpin GmbH, Rheinstetten, Germany) [88]. Experiments were performed in 1:20 dilution 
with FCS/0.9% saline 1:1 (vol/vol), as described previously [18].  
Supplement 92 
 
6.3.2 SUPPLEMENTARY DATA 
 
  
Correlation coefficient between HPLC DOX-
concentration of the medial and lateral parts of the 
heated tumor and the unheated tumor to the corre-
sponding ROI values of: 
r-value p-value 
static 
data  
T1_1FA_treatment_rel [%] -0.875 0.000 
T1_1FA_treatment_abs [ms] -0.826 0.000 
T1_1FA_total_rel [%] -0.782 0.000 
T1_1FA_total_abs [ms] -0.661 0.003 
T1_7FA_rel [%] -0.207 0.410 
T1_7FA_abs [ms] -0.470 0.077 
Phase_abs [rad] -0.842 0.001 
dynamic 
data 
Phase_AUC [rad*s] -0.862 0.000 
T1_1FA_AUC_rel [%*s] -0.843 0.000 
T1_1FA_AUC_abs [ms*s] -0.794 0.000 
Supplementary table 7: Correlation of DOX concentration with different MRI parameters 
with corresponding p-value (0.000  p<0.0005). Medial and lateral parts of the heated tu-
mor and the unheated tumor were used for correlation. 
 
    Doxorubicin concentration [ng/mg] 
  
A       B   
    
DOX heated 
tumor 
Dox unheated 
tumor 
Dox unhea-
ted tumor 
st
at
ic
 d
at
a 
 
T1_1FA_treatment_rel [%] 10.6 (4.1) 1.6 (2.7) 1.7 (2.4) 
T1_1FA_treatment_abs [ms] 10.5 (4.8) 1.8 (3.2) 1.6 (2.6) 
T1_1FA_total_rel [%] 9.7 (6.8) 1.6 (3.9) 2.7 (2.3) 
T1_1FA_total_abs [ms] 9.4 (8.2) 1.7 (6.0) 2.9 (2.9) 
T1_7FA_rel [%] 9.1 (9.59 -3.2 (5.5) 7.0 (2.7) 
T1_7FA_abs [ms] 8.8 (12.1) -2.9 (7.4) 7.0 (3.6) 
Phase_abs [rad] 10.7 (4.8) 2.9 (1.6) 0.4 (1.3) 
d
yn
am
ic
 
d
at
a 
Phase_AUC [rad*s] 10.6 (4.0) 3.5 (1.6) -0.2 (2.3) 
T1_1FA_AUC_rel [%*s] 11.2 (2.4) 3.2 (2.7) -0.4 (3.7) 
T1_1FA_AUC_abs [ms*s] 10.6 (4.7) 2.5 (2.7) 0.8 (1.6) 
  HPLC 10.6 (2.6) 1.2 (0.4) 2.1 (1.1) 
Supplementary table 8: Mean doxorubicin concentration determined for whole tumors by 
MRI and HPLC analysis. ). SD is given in parentheses. 
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    Doxorubicin concentration [ng/mg]  
  
A       B   A+B 
    
Medial  
half 
Lateral  
half 
Medial 
half 
Lateral 
half 
Muscle 
st
at
ic
 d
at
a 
 
T1_1FA_treatment_rel [%] 13.2 (4.3) 9.5 (4.1) 2.9 3.7 0.3 (0.6) 
T1_1FA_treatment_abs 
[ms] 
12.0 (4.4) 
10.2 (4.7) 1.1 3.5 -1.3 (0.7) 
T1_1FA_total_rel [%] 11.6 (8.3) 9.7 (6.1) 4.2 5.1 -6.7 (2.4) 
T1_1FA_total_abs [ms] 9.8 (8.9) 10.6 (7.6) 2.2 5.9 -9.8 (2.5) 
T1_7FA_rel [%] 8.2 (12.1) 9.6 (7.3) 9.6 8.2 -14.4 (3.7) 
T1_7FA_abs [ms] 6.1 (13.2) 11.1 (9.6) 7.8 5.7 -17.4 (3.7) 
Phase_abs [rad] 11.5 (5.3) 10.0 (4.6) 0.9 0.5 -0.5 (0.6) 
d
yn
am
ic
 
d
at
a 
Phase_AUC [rad*s] 11.9 (4.9) 11.1 (3.4) 3.2 1.8 -0.9 (0.5) 
T1_1FA_AUC_rel [%*s] 11.5 (3.1) 9.1 (3.5) -2.9 2.2 -0.7 (1.2) 
T1_1FA_AUC_abs [ms*s] 13.3 (4.8) 8.7 (4.3) 2.8 0.8 -0.4 (1.0) 
  HPLC 14.1 (3.9) 9.0 (3.0) 2.7 2.3 *0.5 (0.1) 
Supplementary table 9: Mean doxorubicin concentration for bisected tumors and non-
heated muscle tissue for MRI and HPLC analysis. *DOX was determined in preceding experi-
ments [87]. SD is given in parentheses. Because group B consisted only of two bisected tu-
mors, values were stated without DS. 
 
linear regression of MRI Parameter and HPLC DOX concentration 
for the lateral, medial heated tumor parts and the unheated tumor 
regression with HPLC DOX-concentration and Slope (m) Intercept (a) r² 
static data 
T1 1FA total abs [ms] -23.44 -371.85 0.468 
T1 1FA total rel [%] -20.17 -22.55 0.612 
T1 1FA treatment abs [ms] -36.55 -370.58 0.709 
T1 1FA treatment rel[%] -2.41 -23.26 0.777 
T1 7FA abs [ms] -16.72 -431.63 0.238 
T1 7FA rel [%] -0.062 -25.11 0.281 
Phase difference [rad] -0.061 0.022 0.538 
dynamic 
data 
AUC of dynamic phase [rad*s] -85.93 -402-02 0.619 
AUC of dynamic T1 [%*s] -8.50*10
-3 -66.01*10-3 0.726 
AUC of dynamic T1 [ms*s] -1.13*10
-5 -9.77*10-5 0.667 
Supplementary table 10: Linear regression of MRI Parameter vs. HPLC DOX concentration. 
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Linear regression of MRI calculated DOX and HPLC DOX concentration 
regression with HPLC DOX and MRI DOX of Slope intercept r² RPC (ng/mg) 
static 
data 
T1_1FA_treatment_rel  0.80 1.18 0.818 5.6 
T1_1FA_treatment_abs 0.78 1.10 0.765 6.6 
T1_1FA_total_rel 0.79 0.40 0.658 9.0 
T1_1FA_total_abs 0.64 1.24 0.550 11.4 
T1_7FA_rel 0.47 2.21 0.405 18.9 
T1_7FA_abs 0.39 2.71 0.377 19.5 
Phase_abs 0.78 1.25 0.760 7.3 
dynamic 
data 
Phase_AUC 0.83 0.78 0.813 5.8 
T1_1FA_AUC_rel 0.78 1.19 0.772 6.9 
T1_1FA_AUC_abs 0.76 1.26 0.721 6.8 
Supplementary table 11: Linear regression for measured vs. calculated DOX values for lat-
eral, medial-heated tumor parts and the unheated tumor ROI in [(ng/mg)/(ng/mg)]. Data 
were generated with data from supplementary table 10. RPC factor is generated from the 
Bland Altman plot. 
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7. ABBREVIATIONS 
AUC area under the curve 
CA contrast agent 
CAD computer-aided design 
cm² square centimeter 
CT computed tomography 
CW continuous wave 
DAM double angle method 
DNA deoxyribonucleic acid 
DOX doxorubicin 
DPPG2 1,2-dipalmitoyl-sn-glycero-3-
phosphodiglycerol 
DSPC 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine 
EPR enhanced permeability and re-
tention 
e.g. for example (exempli gratia) 
FA flip angle 
FCS fetal calf serum 
FID free induction decay 
FUS focused ultrasound 
FOV field of view 
Gd gadolinium 
GRE gradient echo 
HIFU high intense focused ultrasound 
HPLC high pressure liquid chromatog-
raphy 
HT hyperthermia 
i. v. intra venous 
IR infrared 
LITT laser induced thermotherapy 
MRI magnetic resonance imaging 
NIR near infrared 
NMR nuclear magnetic resonance 
 
 
 
 
PDT photo dynamic therapy 
PET positron emission tomography 
Phase_AUC AUC for PRFS 
Phase_diff  absolute PRFS 
PK pharmacokinetic 
PRFS proton resonance frequency 
shift 
RF radio frequency 
ROI region of interest 
RES reticuloendothelial system 
RPC reproducibility coefficient 
SD standard deviation 
SENSE sensitivity encoding 
SNR signal to noise ratio  
SPECT single photon emission comput-
ed tomography 
SR saturation recovery 
T1 longitudinal relaxation time 
T1_1FA_AUC_abs AUC for absolute T1 
change during the treatment 
T1_1FA_AUC_rel AUC for relative T1 
change during the treatment 
T1_1FA_total_abs absolute T1 differ-
ence for total acquisition time 
T1_1FA_total_rel relative T1 difference 
for total acquisition time 
T1_1FA_treatment_rel relative T1 difference 
for the therapy time 
T1_1FA_treatment_abs absolute T1 differ-
ence for the therapy time 
T1_7FA_abs absolute T1 time 
difference for total acquisition 
time measured with 7 FA 
Abbreviations 96 
 
T1_7FA_rel relative T1 time dif-
ference for total acquisition time 
measured with 7 FA 
T2 transversal relaxation time 
TE echo time 
TLC thin layer chromatography 
Tm transition temperature 
TSL thermosensitive liposomes 
TR repetition time 
TWIST time-resolved angiography with 
stochastic trajectories 
UV ultra violet 
VFA variable flip angle 
VOI volume of interest 
W watt 
VOI volume of interest 
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